

Enantioselective Isothiourea-Catalysed Reversible Michael Addition of Aryl Esters to 2-Benzylidene Malononitriles

Alastair J. Nimmo, Jacqueline Bitai, Claire M. Young, Alexandra M. Z. Slawin, David B. Cordes and Andrew D. Smith*

Supporting Information

Table of Contents

1	General Information.....	3
2	General Procedures.....	5
3	Reaction Optimisation	8
4	Unsuccessful Substrates	12
5	Mechanistic Studies.....	12
6	Preparation of vinyl dinitriles	21
7	Preparation of electron-deficient aryl esters.....	26
8	Ester screen products	33
9	Isothiourea catalysis products	37
10	Isolation of CIDT products by filtration	56
11	Gram scale reaction.....	57
12	Product derivatisations	58
13	Single crystal X-ray diffraction data.....	62
14	References.....	66
Appendix I: ^1H , $^{19}\text{F}\{^1\text{H}\}$, $^{13}\text{C}\{^1\text{H}\}$, 2D ^1H COSY, 2D ^1H - ^{13}C HSQC and 2D ^1H - ^{13}C HMBC NMR Spectra.....		67
Appendix II: HPLC traces of novel compounds		288

1 General Information

All reagents and solvents were obtained from commercial suppliers and were used without further purification unless otherwise stated. Reactions involving moisture sensitive reagents were carried out in flame-dried glassware under an inert atmosphere (N_2 or Ar) using standard vacuum line techniques. Anhydrous solvents (Et_2O , CH_2Cl_2 , THF and toluene) were obtained after passing through an alumina column (Mbraun SPS-800). Petrol is defined as petroleum ether 40–60 °C.

Room temperature (RT) refers to 20–25 °C. Reactions involving heating were performed using DrySyn blocks and a contact thermocouple.

Under reduced pressure refers to the use of either a Büchi Rotavapor R-200 with a Büchi V-491 heating bath and Büchi V-800 vacuum controller, a Büchi Rotavapor R-210 with a Büchi V-491 heating bath and Büchi V-850 vacuum controller, a Heidolph Laborota 4001 with vacuum controller, an IKA RV10 rotary evaporator with a IKA HB10 heating bath and ILMVAC vacuum controller, or an IKA RV10 rotary evaporator with a IKA HB10 heating bath and Vacuubrand CVC3000 vacuum controller. Rotary evaporator condensers are fitted to Julabo FL601 Recirculating Coolers filled with ethylene glycol and set to –5 °C.

Analytical thin layer chromatography (TLC) was performed on pre-coated aluminium plates (Kieselgel 60 F254 silica) and visualisation was achieved using ultraviolet light (254 nm) and/or staining with either aqueous $KMnO_4$ solution, ethanolic phosphomolybdic acid, or ethanolic Vanillin solution followed by heating. Manual column chromatography was performed in glass columns fitted with porosity 3 sintered discs over Kieselgel 60 silica using the solvent system stated.

Melting points were recorded on an Electrothermal 9100 melting point apparatus, (dec) refers to decomposition.

Optical rotations were measured on a Perkin Elmer Precisely/Model-341 polarimeter operating at the sodium D line with a 100 mm path cell at 20 °C. Concentrations (c) are stated in g/100 mL.

HPLC analyses were obtained on either a Shimadzu HPLC consisting of a DGU-20A5 degassing unit, LC-20AT liquid chromatography pump, SIL-20AHT autosampler, CMB-20A communications bus module, SPD-M20A diode array detector and a CTO-20A column oven or a Shimadzu HPLC consisting of a DGU-20A5R degassing unit, LC-20AD liquid chromatography pump, SIL-20AHT autosampler, SPD-20A UV/Vis detector and a CTO-20A column oven. Separation was achieved using either a DAICEL CHIRALCEL OD-H column or DAICEL CHIRALPAK AD-H, IA, IB and ID columns using the method stated. HPLC traces of enantiomerically enriched compounds were compared with authentic racemic spectra.


Infrared spectra were recorded on a Shimadzu IRAffinity-1 Fourier transform IR spectrophotometer fitted with a Specac Quest ATR accessory (diamond puck). Spectra were recorded of thin films with characteristic absorption wavenumbers ($\nu_{\max}$) reported in cm^{-1} .

^1H , $^{13}\text{C}\{^1\text{H}\}$, and $^{19}\text{F}\{^1\text{H}\}$ NMR spectra were acquired on either a Bruker AV400 with a BBFO probe (^1H 400 MHz; $^{19}\text{F}\{^1\text{H}\}$ 377 MHz), a Bruker AVII 400 with a BBFO probe (^1H 400 MHz; $^{19}\text{F}\{^1\text{H}\}$ 376 MHz), a Bruker AVIII-HD 500 with a SmartProbe BBFO+ probe (^1H 500 MHz, $^{19}\text{F}\{^1\text{H}\}$ 470 MHz), a Bruker AVIII 500 with a CryoProbe Prodigy BBO probe (^1H 500 MHz, $^{13}\text{C}\{^1\text{H}\}$ 126 MHz), or a Bruker AVIII-HD 700 with a CryoProbe Prodigy TCI probe ($^{13}\text{C}\{^1\text{H}\}$ 176 MHz) in the deuterated solvent stated. All chemical shifts are quoted in parts per million (ppm) relative to the residual solvent peak. All coupling constants, J , are quoted in Hz. Multiplicities are indicated as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and multiples thereof. The abbreviation Ar denotes aromatic. NMR peak assignments were confirmed using 2D ^1H correlated spectroscopy (COSY), 2D ^1H nuclear Overhauser effect spectroscopy (NOESY), 2D ^1H - ^{13}C heteronuclear multiple-bond correlation spectroscopy (HMBC), and 2D ^1H - ^{13}C heteronuclear single quantum coherence (HSQC) where necessary.

Mass spectrometry (m/z) data were acquired by either electrospray ionisation (ESI), electron impact (EI), or matrix-assisted laser desorption/ionisation with no matrix (MALDI (no matrix)) at either the University of St Andrews Mass Spectrometry Facility or SIRCAMS at University of Edinburgh.


2 General Procedures

2.1 General Procedure A: Preparation of 2-benzylidenemalononitriles



Following the procedure of Guo and co-workers,¹ the requisite aldehyde (1.0 equiv.) was dissolved in EtOH (0.7 M) then malononitrile (1.0 equiv.) followed by piperidine (10 mol%) were added. The reaction mixture was stirred at RT. On completion, pentane:Et₂O (9:1) was added to precipitate the product, which was then collected by filtration under vacuum, washing with pentane:Et₂O (9:1).


2.2 General Procedure B: Preparation of electron-deficient aryl 2-*p*-tolylacetates



Method A:² 2-(*p*-tolyl)acetic acid (2.0 equiv.) and EDCI·HCl (1.5 equiv.) were dissolved in CH₂Cl₂ (0.3 M) with stirring. The appropriate phenol (1.0 equiv.) was added, and the reaction stirred at RT. Upon completion, the reaction mixture was diluted with CH₂Cl₂ and extracted with NaHCO₃ (× 2). The organic phase was then dried over MgSO₄ and concentrated *in vacuo* to give the crude product which was purified by flash silica column chromatography as specified.


Method B:³ 2-(*p*-tolyl)acetic acid (1.0 equiv.) and EDCI·HCl (1.3 equiv.) were dissolved in CH₂Cl₂ (0.6 M) with stirring. The appropriate phenol (1.5 equiv.) was added, and the reaction stirred at RT. Upon completion, the reaction mixture was diluted with H₂O and extracted with CH₂Cl₂ (× 3). The organic phase was then dried over MgSO₄ and concentrated *in vacuo* to give the crude product which was purified by flash silica column chromatography as specified.

2.3 General Procedure C: Preparation of 2,3,5,6-tetrafluorophenyl esters




Following the procedure of Smith and co-workers,² the appropriate arylacetic acid (2.0 equiv.) and EDCI·HCl (1.5 equiv.) were dissolved in CH₂Cl₂ (0.3 M) with stirring. 2,3,5,6-Tetrafluorophenol (1.0 equiv.) was added, and the reaction stirred at RT. Upon completion, the reaction mixture was diluted with CH₂Cl₂ and extracted with NaHCO₃ (× 2). The organic phase was then dried over MgSO₄ and concentrated to give the crude product which was purified by flash silica column chromatography as specified.

2.4 General Procedure D: Screening electron-deficient aryl esters



To an oven-dried vial was added the appropriate electron-deficient aryl 2-*p*-tolylacetate (0.75 mmol, 1.5 equiv.), 2-benzylidene malononitrile (78 mg, 0.50 mmol, 1.0 equiv.), and (*R*)-BTM (6.3 mg, 0.025 mmol, 5 mol%). The vial was sealed and purged before CH₂Cl₂ (0.5 M) was added and the reaction stirred at RT for 24 h. The reaction was stopped by removal of the solvent under reduced pressure. The crude product was purified by flash silica column chromatography as specified.

2.5 General Procedure E: Isothiourea-catalysed enantioselective Michael addition




To an oven-dried vial was added the appropriate 2,3,5,6-tetrafluorophenyl ester (0.75 mmol, 1.5 equiv.), vinyl dinitrile (0.50 mmol, 1.0 equiv.), and (4bR,11aS)-fused-BTM **19** (6.6 mg, 0.025 mmol, 5 mol%). The vial was sealed and purged before CPME (1.0 M) was added and the reaction stirred at RT for 24 h. The reaction was stopped by removal of the solvent under reduced pressure. The crude product was purified by flash silica column chromatography as specified.

3 Reaction Optimisation

All optimisation reactions were performed on a 0.5 mmol scale.

3.1 Screen of electron-deficient aryl esters

Table S1: Influence of electron-deficient aryl ester.




Entry	Ester	dr ^[a]	er ^[b]	er ^[b]	Yield ^[c] (%)
		<i>anti:syn</i>	<i>anti</i>	<i>syn</i>	
1	1	49:51	79:21	93:7	58
2	6	48:52	87:13	97:3	48
3	7	-	-	-	0
4	8	74:26	89:11	93:7	48
5	9	68:32	89:11	95:5	51

[a] Determined by ¹H NMR analysis. [b] Determined by chiral HPLC analysis of a mixture of diastereoisomers. [c] Combined isolated yield of diastereoisomers.

3.2 Screen of reaction conditions

Table S2: Optimisation of reaction conditions.




Entry	Catalyst (mol%)	Concentration (M)	Temperature (°C)	dr ^[a] <i>anti:syn</i>	er ^[b] <i>anti</i>	er ^[b] <i>syn</i>	Yield ^[c] (%)
1	5	0.5	RT	68:32	89:11	95:5	51
2	5	1.0	RT	72:28	87:13	94:6	72
3	5	2.0	RT	76:24	89:11	90:10	70
4	10	1.0	RT	85:15	85:15	83:17	76
5	5	1.0	40	83:17	82:18	82:18	64

[a] Determined by ^1H NMR analysis. [b] Determined by chiral HPLC analysis of a mixture of diastereoisomers. [c] Combined isolated yield of diastereoisomers.

3.3 Screen of solvents

Table S3: Solvent screen.



Entry	Solvent	dr ^[a]	er ^[b]	er ^[b]	Yield ^[c]
		<i>anti:syn</i>	<i>anti</i>	<i>syn</i>	
1	CH ₂ Cl ₂	72:28	87:13	94:6	72
2	PhMe	74:26	77:23	95:5	67
3	THF	52:48	82:18	92:8	69
4 ^[d]	Et ₂ O	75:25	89:11	92:8	80
5	1,4-Dioxane	65:35	90:10	95:5	75
6	MeOH	-	-	-	0
7	MeCN	38:62	47:53	81:19	62
8	DMF	26:74	35:65	77:23	23
9 ^[d]	EtOAc	68:32	82:18	90:10	78
10	CHCl ₃	77:23	91:9	97:3	54
11 ^[d]	TBME	83:17	89:11	90:10	75
12 ^[d]	CPME	83:17	90:10	92:8	77
13	DME	62:38	78:22	87:13	70
14	IPA	69:31	82:18	89:11	70
15 ^[d]	DMC	66:34	85:15	94:6	76

[a] Determined by ¹H NMR analysis. [b] Determined by chiral HPLC analysis of a mixture of diastereoisomers. [c] Combined isolated yield of diastereoisomers. [d] Precipitation of products observed.

3.4 Screen of isothiourea catalysts

Table S4: Screening of catalysts with extended reaction time.


Reaction scheme: 9 (1.5 equiv.) + 2 (isothiourea) in Et₂O (1.0 M) at RT yields *anti*-14 and *syn*-15.

Catalysts: (R)-BTM (**3**), (S)-TM (**16**), (2S,3R)-HyperBTM (**17**), (S)-i-Pr-BTM (**18**), (4bR,11aS)-fused-BTM (**19**)

Entry	Catalyst (mol%)	Reaction time (h)	dr ^[a] <i>anti:syn</i>	er ^[b] <i>anti</i>	er ^[b] <i>syn</i>	Yield ^[c] (%)
1	(R)-BTM 3 (5)	48	>95:5	88:12	-	Quant.
2	(R)-BTM 3 (20)	24	>95:5	87:13	-	86
3	(S)-TM 16 (20)	168	74:26	87:13 ^[d]	>99:1 ^[d]	45
4	(2S,3R)-HyperBTM 17 (5)	24	>95:5	79:21	-	99
5	(S)-i-Pr-BTM 18 (5)	96	>95:5	98:2 ^[d]	-	99
6	(4bR,11aS)-fused-BTM 19 (5)	24	95:5	99:1	-	91

[a] Determined by ¹H NMR analysis. [b] Determined by chiral HPLC analysis of a mixture of diastereoisomers. [c] Combined isolated yield of diastereoisomers. [d] opposite major enantiomer.

4 Unsuccessful Substrates




2,3,5,6-Tetrafluorophenyl ester **33** and vinyl dinitriles **34** and **35** were completely unreactive returning only the starting materials. Vinyl dinitrile **36** reacted poorly giving around 20% conversion in 24 h.

5 Mechanistic Studies

For all reactions the yield was determined by ^1H NMR with 1,3,5-trimethoxybenzene as internal standard.


5.1 PNP Ester




A single diastereoisomer of either *anti*-**4** or *syn*-**5** (21.3 mg, 0.05 mmol, 1.0 equiv.) and either (*R*)-BTM (0.6 mg, 0.0025 mmol, 5 mol%) or NBu₄OPNP (1.0 mg, 0.0025 mmol, 5 mol%) were weighed into an oven-dried vial. The vial was capped and purged before addition of CH₂Cl₂ (0.5 M) and the reaction stirred at RT for 24 h.

5.2 TeFP Ester

Tetrabutylammonium 2,3,5,6-tetrafluorophenoxide (S1)



Adapting the procedure of Mayr and co-workers,⁴ to a stirred solution of 2,3,5,6-tetrafluorophenol (0.50 g, 3.0 mmol, 1.5 equiv.) in MeOH (0.7 M) was added slowly tetrabutylammonium hydroxide (40% in H₂O) (1.3 mL, 2.0 mmol, 1.0 equiv.). The reaction mixture was stirred at RT for 10 min then the solvent was removed to give the crude product as a colourless solid. The crude product was dissolved in Et₂O then filtered. The filtrate was then concentrated under reduced pressure and triturated with hexane to afford the title compound as a colourless solid (206 mg, 25%). **mp** 47–49 °C; **IR** ν_{max} (film) 3175 (br), 2959 (C–H), 2934, 2874, 1634, 1564, 1504, 1485, 1383, 1271, 1155, 1101, 926, 881; **¹H NMR** (400 MHz, MeOD) δ_{H} : 1.04 (12H, t, J 7.3, NCH₂CH₂CH₂CH₃), 1.37 – 1.49 (8H, m, NCH₂CH₂CH₂CH₃), 1.63 – 1.73 (8H, m, NCH₂CH₂CH₂CH₃), 3.21 – 3.29 (8H, m, NCH₂CH₂CH₂CH₃), 6.05 (1H, tt, J 10.9, 6.9, ArC(4)H); **¹⁹F{¹H} NMR** (377 MHz, MeOD) δ_{F} : -168.7 – -168.5 (m), -148.3 – -148.1 (m); **¹³C{¹H} NMR** (126 MHz, MeOD) δ_{C} : 12.5 (NCH₂CH₂CH₂CH₃), 19.3 (NCH₂CH₂CH₂CH₃), 23.4 (NCH₂CH₂CH₂CH₃), 58.1 (NCH₂CH₂CH₂CH₃), 85.6 (t, J 24.3, ArC(4)H), 139.7 – 141.9 (m, ArCF), 145.7 – 148.3 (m, ArCF and ArC(1)); **HRMS** (ESI^+) C₁₆H₃₆N [M]⁺ found 242.2854, requires 242.2842 (+4.8 ppm), (ESI^-) C₆HOF₄ [M]⁻ found 164.9962, requires 164.9969 (-4.2 ppm).




Background Reaction

Adapting General Procedure E by replacing (4bR,11aS)-fused-BTM **19** with NBu₄OTeFP **S1**, 2,3,5,6-tetrafluorophenyl 2-(p-tolyl)acetate **9** (112 mg, 0.38 mmol, 1.5 equiv.), 2-


benzylidene malononitrile **2** (38.5 mg, 0.25 mmol, 1.0 equiv.), and NBu₄OTeFP **S1** (5.1 mg, 0.013 mmol, 5 mol%) in CPME (1.0 M) gave only *anti*-**14** (15%).

Retro-Michael Reactions



A single diastereoisomer of either *anti*-**14** or *syn*-**15** (22.6 mg, 0.05 mmol, 1.0 equiv.) and either (*R*)-BTM **3** (0.6 mg, 0.0025 mmol, 5 mol%) or NBu₄OTeFP **S1** (1.0 mg, 0.0025 mmol, 5 mol%) were weighed into an oven-dried vial. The vial was capped and purged before addition of CH₂Cl₂ (0.5 M) and the reaction stirred at RT for 24 h.

Retro-Michael Reactions in Optimised Conditions



Enantiopure (>99:1 er) *anti*-**14** and either (4*bR*,11*aS*)-fused-BTM **19** or NBu₄OTeFP **S1** were weighed into an oven-dried vial. The vial was sealed and purged before CPME was added and the reaction mixture stirred at RT for 24 h.

In 1.0 M CPME *anti*-**14** was not very soluble, as demonstrated by it precipitating during the catalysis. Under these conditions, without any other additives *anti*-**14** was stable to the retro reaction (Table S5, Entry 1). Adding (4*bR*,11*aS*)-fused-BTM **19** promoted the retro-reaction, but with only slight (6%) conversion to starting materials **9** and **2** (Table S5,

Entry 2). Similarly, adding NBu₄OTeFP **S1** gave 4% starting materials **9** and **2**, with most of *anti*-**14** intact (Table S5, Entry 3).

Table S5: Retro-Michael reaction in CPME (1.0 M)

Entry	(4 <i>bR</i> ,11 <i>aS</i>)- 19 (5 mol%)	NBu ₄ OTeF P (5 mol%)	<i>Anti</i> - 14 (%)	<i>Syn</i> - 15 (%)	9 + 2 (%)
1	No	No	100	0	0
2	Yes	No	94	0	6
3	No	Yes	96	0	4


To account for the relative concentration of *anti*-**14** as it is being formed during the catalysis, the control reactions were also carried out in 0.05 M CPME. Again, without any additives *anti*-**14** was stable to retro reaction (Table S6, Entry 1). Adding (4*bR*,11*aS*)-fused-BTM **19** promoted the retro reaction giving 33% starting materials **9** and **2**. Also, (4*bR*,11*aS*)-fused-BTM **19** catalysed the forward reaction producing 9% *syn*-**15**. The major (2*R*,3*R*) enantiomer of the *syn*-**15** is consistent with the catalysis and not from epimerisation (Table S6, Entry 2). Adding NBu₄OTeFP **S1** gave 24% starting materials **9** and **2**, but no epimerisation to *syn*-**15** was observed (Table S6, Entry 3).

Table S6: Retro-Michael reaction in CPME (0.05 M)

Entry	(4 <i>bR</i> ,11 <i>aS</i>)- 19 (5 mol%)	NBu ₄ OTeF P (5 mol%)	<i>Anti</i> - 14 (%)	<i>Syn</i> - 15 (%)	9 + 2 (%)
1	No	No	100	0	0
2	Yes	No	58 (99:1 er)	9 (96:4 er)	33
3	No	Yes	76	0	24


In conclusion, both (4b*R*,11a*S*)-fused-BTM **19** and NBu₄OTeFP **S1** promoted the retro-Michael reaction. Precipitation of *anti*-**14** from the reaction mixture was beneficial to minimise the retro-Michael reaction.

5.3 ^1H NMR Reaction Monitoring




2,3,5,6-tetrafluorophenyl 2-(p-tolyl)acetate **9** (134 mg, 0.45 mmol, 1.5 eq), 2-benzylidene malononitrile **2** (46.3 mg, 0.30 mmol, 1.0 eq), (R)-BTM **3** (3.8 mg, 0.015 mmol, 5 mol%) and 1,3,5-trimethoxybenzene (16.8 mg, 0.10 mmol, 0.33 eq) were dissolved in CD_2Cl_2 then transferred into an NMR tube. A ^1H NMR spectrum was obtained 10 times over the course of 48 h.

Figure S1: Diastereomeric excess over time.



5.4 Probing Transesterification of Catalysis Product

anti-2,3,5,6-tetrafluorophenyl 3-phenyl-4,4-bis(phenylsulfonyl)-2-(*p*-tolyl)butanoate (S2) and *syn*-2,3,5,6-tetrafluorophenyl 3-phenyl-4,4-bis(phenylsulfonyl)-2-(*p*-tolyl)butanoate (S3)




2,3,5,6-tetrafluorophenyl 2-(*p*-tolyl)acetate **9** (224 mg, 0.75 mmol, 1.5 equiv.), (2-phenylethene-1,1-diyl)disulfonyldibenzene (192 mg, 0.50 mmol, 1.0 equiv.), and ($\pm$)-BTM **3** (12.6 mg, 0.05 mmol, 10 mol%) were dissolved in anhydrous CH_2Cl_2 (0.5 M) and the reaction mixture stirred at RT for 24 h. Once complete, the solvent was removed under reduced pressure to give the crude product that was purified by flash silica column chromatography (CH_2Cl_2 :hexane 75:25, R_F 0.27) to give the combined *anti* and *syn* diastereoisomers (71:29 dr) (95 mg, 28%) as an inseparable mixture as a colourless solid. **mp** 78–80 °C; **IR** ν_{max} (film) 3069, 1778 (C=O, ester), 1524, 1485, 1449, 1331, 1312, 1159, 1146, 1105, 957, 907, 800; **HRMS** (ESI^+) $\text{C}_{35}\text{H}_{26}\text{O}_6\text{S}_2\text{F}_4\text{Na}$ $[M + \text{Na}]^+$ found 705.0981, requires 705.0999 (+2.6 ppm).

Data for *anti*-S2: ^1H NMR (500 MHz, CDCl_3) δ_{H} : 2.49 (3H, s, CH_3), 4.81 (1H, d, J 1.5, C(4)H), 4.97 (1H, dd, J 12.4, 1.5, C(3)H), 5.49 (1H, d, J 12.4, C(2)H), 6.90 (1H, tt, J 9.8, 6.8, $\text{Ar}^1\text{C}(4)\text{H}$), 7.21 – 7.34 (8H, m, $\text{Ar}^2\text{C}(2,3,5,6)\text{H}$ and $\text{Ph}^1\text{C}(2,6)\text{H}$ and $\text{Ph}^2\text{C}(2,6)\text{H}$), 7.34 – 7.63 (9H, m, $\text{Ar}^3\text{C}(3,4,5)\text{H}$ and $\text{Ph}^1\text{C}(3,4,5)\text{H}$ and $\text{Ph}^2\text{C}(3,4,5)\text{H}$), 7.86 – 7.90 (2H, m, $\text{Ar}^3\text{C}(2,6)\text{H}$); $^{19}\text{F}\{^1\text{H}\}$ NMR (470 MHz, CDCl_3) δ_{F} : -152.6 – -152.4 (m), -139.1 – -139.0 (m); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ_{C} : 21.3 (CH_3), 46.1 (C(3)H), 54.3 (C(2)H), 82.4 (C(4)H), 103.3 (t, J 22.9, $\text{Ar}^1\text{C}(4)\text{H}$), 128.3 ($\text{Ph}^2\text{C}(2,6)\text{H}$), 128.4 ($\text{Ph}^1\text{C}(2,6)\text{H}$), 128.6 ($\text{Ar}^3\text{C}(4)\text{H}$), 128.7 ($\text{Ph}^2\text{C}(3,5)\text{H}$), 128.9 ($\text{Ar}^3\text{C}(3,5)\text{H}$), 129.0 ($\text{Ph}^1\text{C}(3,5)\text{H}$), 129.1 – 129.4 (m, $\text{Ar}^1\text{C}(1)$), 129.5 ($\text{Ar}^2\text{C}(2,6)\text{H}$), 130.4 – 130.7 (m, $\text{Ar}^2\text{C}(3,5)\text{H}$ and $\text{Ar}^3\text{C}(2,6)\text{H}$), 131.6 ($\text{Ar}^2\text{C}(1)$), 133.6 ($\text{Ar}^3\text{C}(1)$), 134.0 ($\text{Ph}^2\text{C}(4)\text{H}$), 134.0 ($\text{Ph}^1\text{C}(4)\text{H}$), 138.6 ($\text{Ph}^2\text{C}(1)$), 139.4 ($\text{Ar}^2\text{C}(4)$), 140.1 ($\text{Ph}^1\text{C}(1)$), 139.2 – 141.5 (m, Ar^1CF), 144.6 – 146.9 (m, Ar^1CF), 168.1 (C(1)).


Data for *syn*-**S3**: ^1H NMR (500 MHz, CDCl_3) (*selected*) δ_{H} : 2.26 (3H, s, CH_3), 4.78 (1H, dd, J 11.9, 3.1, $\text{C}(3)\text{H}$), 5.45 (1H, d, J 11.9, $\text{C}(2)\text{H}$), 5.86 (1H, d, J 3.1, $\text{C}(4)\text{H}$), 6.98 – 7.10 (5H, m, $\text{Ar}^1\text{C}(4)\text{H}$ and $\text{Ar}^2\text{C}(2,3,5,6)\text{H}$), 7.76 – 7.81 (2H, m, $\text{Ar}^3\text{C}(2,6)\text{H}$); $^{19}\text{F}\{^1\text{H}\}$ NMR (470 MHz, CDCl_3) δ_{F} : -152.5 – -152.3 (m), -138.7 – -138.5 (m); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) (*selected*) δ_{C} : 21.1 (CH_3), 48.0 ($\text{C}(3)\text{H}$), 54.3 ($\text{C}(2)\text{H}$), 83.1 ($\text{C}(4)\text{H}$), 103.6 (t, J 22.8, $\text{Ar}^1\text{C}(4)\text{H}$), 128.8 ($\text{Ar}^3\text{C}(3,5)\text{H}$), 129.0 ($\text{Ph}^1\text{C}(3,5)\text{H}$), 129.5 ($\text{Ar}^2\text{C}(3,5)\text{H}$), 133.1 ($\text{Ar}^3\text{C}(1)$), 134.2 ($\text{Ph}^2\text{C}(4)\text{H}$), 134.2 ($\text{Ph}^1\text{C}(4)\text{H}$), 137.9 ($\text{Ar}^2\text{C}(4)$), 138.6 ($\text{Ph}^2\text{C}(1)$), 139.4 – 141.7 (m, Ar^1CF), 140.6 ($\text{Ph}^1\text{C}(1)$), 144.8 – 147.2 (m, Ar^1CF), 170.7 ($\text{C}(1)$).

***anti*-4-nitrophenyl 3-phenyl-4,4-bis(phenylsulfonyl)-2-(*p*-tolyl)butanoate (**S4**)**



4-nitrophenyl 2-(*p*-tolyl)acetate **1** (203 mg, 0.75 mmol, 1.5 equiv.), (2-phenylethene-1,1-diyl)disulfonyldibenzene (192 mg, 0.50 mmol, 1.0 equiv.), and ($\pm$)-BTM **3** (12.6 mg, 0.05 mmol, 10 mol%) were dissolved in anhydrous CH_2Cl_2 (0.5 M) and the reaction mixture stirred at RT for 24 h. Once complete, the solvent was removed under reduced pressure to give the crude product (89:11 dr) that was purified by flash silica column chromatography (hexane:EtOAc 85:15 to 50:50, R_{F} 0.11 at 75:25) to give the title compound (134 mg, 41%) as a colourless solid. **mp** 167–169 °C; **IR** ν_{max} (film) 3063, 1761 ($\text{C}=\text{O}$, ester), 1593, 1526, 1447, 1346, 1202, 1159, 1148, 1121, 1080, 860; ^1H NMR (400 MHz, CD_2Cl_2) δ_{H} : 2.50 (3H, s, CH_3), 4.74 (1H, d, J 1.7, $\text{C}(4)\text{H}$), 4.81 (1H, dd, J 12.4, 1.7, $\text{C}(3)\text{H}$), 5.38 (1H, d, J 12.4, $\text{C}(2)\text{H}$), 6.67 – 6.73 (2H, m, $\text{Ar}^1\text{C}(2,6)\text{H}$), 7.19 – 7.24 (2H, m, $\text{Ph}^2\text{C}(2,6)\text{H}$), 7.30 – 7.41 (6H, m, $\text{Ar}^2\text{C}(3,5)\text{H}$ and $\text{Ph}^1\text{C}(3,5)\text{H}$ and $\text{Ph}^2\text{C}(3,5)\text{H}$), 7.43 – 7.53 (7H, m, $\text{Ar}^2\text{C}(2,6)\text{H}$ and $\text{Ar}^3\text{C}(3,4,5)\text{H}$ and $\text{Ph}^1\text{C}(2,6)\text{H}$), 7.55 – 7.63 (2H, m, $\text{Ph}^1\text{C}(4)\text{H}$ and $\text{Ph}^2\text{C}(4)\text{H}$), 7.93 – 7.98 (2H, m, $\text{Ar}^3\text{C}(2,6)\text{H}$), 8.09 – 8.15 (2H, m, $\text{Ar}^1\text{C}(3,5)\text{H}$); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CD_2Cl_2) δ_{C} : 21.0 (CH_3), 47.2 ($\text{C}(3)\text{H}$), 54.9 ($\text{C}(2)\text{H}$), 81.6 ($\text{C}(4)\text{H}$), 122.1 ($\text{Ar}^1\text{C}(2,6)\text{H}$), 125.0 ($\text{Ar}^1\text{C}(3,5)\text{H}$), 128.1 ($\text{Ph}^2\text{C}(2,6)\text{H}$), 128.2 ($\text{Ph}^1\text{C}(2,6)\text{H}$), 128.5 ($\text{Ar}^3\text{C}(3,5)\text{H}$), 128.6 ($\text{Ar}^3\text{C}(4)\text{H}$), 128.9

(Ph²C(3,5)H), 129.3 (Ar²C(2,6)H and Ph¹C(3,5)H), 130.5 (Ar²C(3,5)H), 131.2 (Ar³C(2,6)H), 131.7 (Ar²C(1)), 134.2 (Ph²C(4)H), 134.2 (Ph¹C(4)H), 134.4 (Ar³C(1)), 138.3 (Ph²C(1)), 139.5 (Ar²C(4)), 140.5 (Ph¹C(1)), 145.4 (Ar¹C(4)), 155.0 (Ar¹C(1)), 169.9 (C(1)). **HRMS** (*ESI*⁻) C₃₅H₂₈O₈S₂N [*M* - *H*]⁻ found 654.1247, requires 654.1262 (-2.3 ppm).




Transesterification Procedure

2,3,5,6-tetrafluorophenyl 3-phenyl-4,4-bis(phenylsulfonyl)-2-(p-tolyl)butanoate **S2:S3** (71:29 dr, 13.7 mg, 0.02 mmol, 1.0 equiv.), 1,3,5-trimethoxybenzene (3.4 mg, 0.02 mmol, 1.0 equiv.), and (*R*)-BTM **3** (0.25 mg, 0.001 mmol, 5 mol%) *AND/OR* NBu₄OPNP (7.6 mg, 0.02 mmol, 1.0 equiv.) were dissolved in CD₂Cl₂ then transferred into an NMR tube. A ¹H NMR spectrum was obtained 9 times over the course of 24 h.

No retro-Michael products were observed in any of the reactions. The reaction with only NBu₄OPNP added showed there was no transesterification in the absence of (*R*)-BTM **3**. There was also no transesterification observed when both NBu₄OPNP and (*R*)-BTM **3** were added. These results suggest the final step in the catalysis (catalyst turnover) is irreversible.


5.5 Crossover Through Retro-Michael Reaction



($\pm$)-*anti*-2,3,5,6-tetrafluorophenyl 4,4-dicyano-3-phenyl-2-(*p*-tolyl)butanoate **14** (45.2 mg, 0.1 mmol, 1.0 equiv.), 2,3,5,6-tetrafluorophenyl 2-(4-methoxyphenyl)acetate **40** (31.4 mg, 0.1 mmol, 1.0 equiv.), and (4*bR*,11*aS*)-fused-BTM **19** (1.3 mg, 0.005 mmol, 5 mol%) were dissolved in CPME (1.0 M) and stirred at RT for 24 h. Once complete the solvent was removed under reduced pressure and ^1H NMR analysis showed 13% yield of (2*R*,3*S*)-2,3,5,6-tetrafluorophenyl 4,4-dicyano-2-(4-methoxyphenyl)-3-phenylbutanoate **20**. The er was determined to be 99:1 by HPLC analysis on a chiral stationary phase after purification by flash silica column chromatography. For HPLC and chromatography conditions see section 9.


6 Preparation of vinyl dinitriles

2-(4-Fluorobenzylidene)malononitrile (S5)




Following General Procedure A, 4-fluorobenzaldehyde (2.48 g, 2.15 mL, 20 mmol), malononitrile (1.32 g, 20 mmol) and piperidine (0.17 g, 0.20 mL, 2 mmol) in EtOH (30 mL) gave the title compound as yellow crystals (2.58 g, 75%). **mp** 118-120 °C {lit⁵ 125-126 °C}; **IR** ν_{max} (film) 3038 (C-H), 2230 (C $\equiv$ N, nitrile), 1599, 1576, 1508, 1416, 1304, 1240, 1161, 1109, 837; **¹H NMR** (400 MHz, CDCl₃) δ_{H} : 7.22 – 7.31 (2H, m, ArC(3,5)H), 7.77 (1H, s, C(2)H), 7.94 – 8.03 (2H, m, ArC(2,6)H). **¹⁹F{¹H} NMR** (376 MHz, CDCl₃) δ_{F} : -100.0 (s); **¹³C{¹H} NMR** (126 MHz, CDCl₃) δ_{C} : 82.4 (d, $^6J_{\text{CF}}$ 2.7, C(1)), 112.5 (CN), 113.6 (CN), 117.2 (d, $^2J_{\text{CF}}$ 22.5, ArC(3,5)H), 127.4 (d, $^4J_{\text{CF}}$ 3.4, ArC(1)), 133.5 (d, $^3J_{\text{CF}}$ 9.5, ArC(2,6)H), 158.4 (C(2)H), 166.1 (d, $^1J_{\text{CF}}$ 260.3, ArC(4)); **HRMS** (EI^+) C₁₀H₅N₂F [M]⁺ found 172.0436, requires 172.0431 (+2.9 ppm).

2-(4-Methoxybenzylidene)malononitrile (S6)




Following General Procedure A, 4-methoxybenzaldehyde (1.36 g, 1.22 mL, 10 mmol), malononitrile (0.66 g, 10 mmol) and piperidine (0.085 g, 0.10 mL, 1 mmol) in EtOH (15 mL) gave the title compound as yellow crystals (1.58 g, 86%). **mp** 110-112 °C {lit⁶ 103-107 °C}; **IR** ν_{max} (film) 2220 (C $\equiv$ N, nitrile), 1605, 1570, 1557, 1512, 1369, 1277, 1180, 1153, 1020, 833; **¹H NMR** (400 MHz, CDCl₃) δ_{H} : 3.94 (3H, s, CH₃), 7.00 – 7.08 (2H, m, ArC(3,5)H), 7.68 (1H, s, C(2)H), 7.90 – 7.98 (2H, m, ArC(2,6)H). **¹³C{¹H} NMR** (126 MHz, CDCl₃) δ_{C} : 55.9 (OCH₃), 78.5 (C(1)), 113.4 (CN), 114.5 (CN), 115.2 (ArC(3,5)H), 124.0 (ArC(1)), 133.5 (ArC(2,6)H), 158.9 (C(2)H), 164.8 (ArC(4)); **HRMS** (EI^+) C₁₁H₈N₂O [M]⁺ found 184.0632, requires 184.0631 (+0.5 ppm).

2-(4-Nitrobenzylidene)malononitrile (S7)




Following General Procedure A, 4-nitrobenzaldehyde (1.51 g, 10 mmol), malononitrile (0.66 g, 10 mmol) and piperidine (0.085 g, 0.10 mL, 1.0 mmol) in EtOH (15 mL) gave the title compound as brown crystals (1.43 g, 72%). **mp** 156-158 °C {lit⁷ 160-162 °C}; **IR** $\nu_{\max}$ (film) 3117 (C-H), 2232 (C $\equiv$ N, nitrile), 1580, 1522, 1344, 1321, 1304, 1213, 935, 851; **¹H NMR** (400 MHz, CDCl₃) δ_{H} : 7.91 (1H, s, C(2)*H*), 8.07 – 8.14 (2H, m, ArC(2,6)*H*), 8.38 – 8.45 (2H, m, ArC(3,5)*H*). **¹³C{¹H} NMR** (126 MHz, CDCl₃) δ_{C} : 87.5 (C(1)), 111.6 (CN), 112.6 (CN), 124.7 (ArC(2,6)*H*), 131.3 (ArC(3,5)*H*), 135.8 (ArC(1)), 150.4 (ArC(4)), 156.9 (C(2)*H*); **HRMS** (*ESI*[−]) C₁₀H₆N₃O₂ [*M* + *H*][−] found 200.0467, requires 200.0466 (+0.5 ppm).

2-(4-Chlorobenzylidene)malononitrile (S8)




Following General Procedure A, 4-chlorobenzaldehyde (0.70 g, 5.0 mmol), malononitrile (0.33 g, 5.0 mmol) and piperidine (0.043 g, 0.05 mL, 0.50 mmol) in EtOH (10 mL) gave the title compound as white crystals (0.75 g, 80%). **mp** 154-156 °C; **IR** $\nu_{\max}$ (film) 3034 (C-H), 2228 (C $\equiv$ N, nitrile), 1585, 1557, 1491, 1406, 1294, 1221, 1096, 935, 829, 814; **¹H NMR** (400 MHz, CDCl₃) δ_{H} : 7.51 – 7.59 (2H, m, ArC(3,5)*H*), 7.76 (1H, s, C(2)*H*), 7.84 – 7.92 (2H, m, ArC(2,6)*H*); **¹³C{¹H} NMR** (126 MHz, CDCl₃) δ_{C} : 83.3 (C(1)), 112.4 (CN), 113.5 (CN), 129.3 (ArC(1)), 130.1 (ArC(2,6)*H*), 131.9 (ArC(3,5)*H*), 141.2 (ArC(4)), 158.3 (C(2)*H*); **HRMS** (*EI*⁺) C₁₀H₅N₂³⁵Cl [*M*]⁺ found 188.0134, requires 188.0136 (-1.1 ppm).

2-(4-(Trifluoromethyl)benzylidene)malononitrile (S9)



Following General Procedure A, 4-(trifluoromethyl)benzaldehyde (0.87 g, 5.0 mmol), malononitrile (0.33 g, 5.0 mmol) and piperidine (0.043 g, 0.05 mL, 0.5 mmol) in EtOH (10 mL) gave the title compound as white crystals (0.19 g, 17%). The filtrate was concentrated under reduced pressure to give crude product which was purified by flash silica column chromatography (Petrol:CH₂Cl₂ 3:1 to 1:1, R_f 0.18 (2:1)) to give the title compound as a colourless solid (0.18 g, 16%). The products were combined to give a total yield of 0.37 g, 33%. **mp** 100-102 °C {lit⁷ 107-109 °C }; **IR** $\nu_{\max}$ (film) 3034 (C-H), 2236 (C≡N, nitrile), 1591, 1566, 1418, 1319, 1167, 1126, 1117, 1070, 1015, 945, 849, 837; **¹H NMR** (400 MHz, CDCl₃) δ_{H} : 7.80 – 7.85 (2H, m, ArC(2,6)H), 7.87 (1H, s, CH), 8.01 – 8.08 (2H, m, ArC(3,5)H). **¹⁹F{¹H} NMR** (376 MHz, CDCl₃) δ_{F} : -63.5 (s); **¹³C{¹H} NMR** (126 MHz, CDCl₃) δ_{C} : 86.0 (C(1)), 111.9 (CN), 113.0 (CN), 123.1 (q, ¹J_{CF} 273.0, CF₃), 126.6 (q, ³J_{CF} 3.8, ArC(3,5)H), 130.8 (ArC(2,6)H), 133.7 (ArC(1)), 135.3 (q, ²J_{CF} 33.3, ArC(4)), 158.1 (C(2)H); **HRMS** (*ESI*⁻) C₁₁H₆N₂F₃ [*M* + *H*]⁻ found 223.0491, requires 223.0489 (+0.9 ppm).


2-(3-(Trifluoromethyl)benzylidene)malononitrile (S10)



3-(Trifluoromethyl)benzaldehyde (1.34 mL, 10.0 mmol, 1.0 equiv.) was dissolved in EtOH (20 mL) with stirring. Malononitrile (0.66 g, 10.0 mmol, 1.0 equiv.) then piperidine (0.10 mL, 1.0 mmol, 0.1 equiv.) were added and the reaction mixture stirred at RT for 4.5 h. Once complete, the solvent was removed under reduced pressure. The crude product was purified by flash silica column chromatography (Hexane:EtOAc 4:1, R_f 0.44) to give the title compound as a colourless solid (1.58 g, 71%). **mp** 75-77 °C; **IR** $\nu_{\max}$ (film) 2230 (C≡N, nitrile), 1595, 1325, 1294, 1165, 1123, 1074, 808; **¹H NMR** (500 MHz, CDCl₃) δ_{H} : 7.71 – 7.77 (1H, m, ArC(5)H), 7.86 – 7.93 (2H, m, C(2)H and ArC(4)H), 8.09 (1H, s, ArC(2)H), 8.18 – 8.24 (1H, m, ArC(6)H); **¹⁹F{¹H} NMR** (376 MHz, CDCl₃) δ_{F} : -63.2 (s); **¹³C{¹H} NMR** (126


MHz, CDCl₃) δ_{C} : 85.3 (C(1)), 112.0 (CN), 113.1 (CN), 123.2 (q, $^1J_{\text{CF}}$ 272.8, CF₃), 127.7 (q, $^3J_{\text{CF}}$ 3.9, ArC(2)H), 130.4 (ArC(5)H), 130.7 (q, $^3J_{\text{CF}}$ 3.6, ArC(4)H), 131.4 (ArC(1)), 132.2 (q, $^2J_{\text{CF}}$ 33.3, ArC(3)), 132.9 (ArC(6)H), 158.2 (C(2)H); **HRMS** (*MALDI (no matrix)*⁺) C₁₁H₅N₂F₃Na [*M* + *Na*]⁺ found 245.0290, requires 245.0297 (-2.9 ppm).

2-(2-(Trifluoromethyl)benzylidene)malononitrile (S11)



2-(Trifluoromethyl)benzaldehyde (1.32 mL, 10.0 mmol, 1.0 equiv.) was dissolved in EtOH (20 mL) with stirring. Malononitrile (0.66 g, 10.0 mmol, 1.0 equiv.) then piperidine (0.10 mL, 1.0 mmol, 0.1 equiv.) were added and the reaction mixture stirred at RT for 4.5 h. Once complete, the solvent was removed under reduced pressure. The crude product was purified by flash silica column chromatography (Hexane:EtOAc 4:1, *R_f* 0.42) to give the title compound as a colourless oil (2.00 g, 90%). **IR** ν_{max} (film) 2234 (C $\equiv$ N, nitrile), 1572, 1315, 1304, 1177, 1109, 1061, 1036, 766; **¹H NMR** (400 MHz, CDCl₃) δ_{H} : 7.71 – 7.81 (2H, m, ArC(4,5)H), 7.84 – 7.90 (1H, m, ArC(3)H), 8.06 – 8.13 (1H, m, ArC(6)H), 8.25 (1H, q, $^5J_{\text{HF}}$ 1.9, C(2)H); **¹⁹F{¹H} NMR** (376 MHz, CDCl₃) δ_{F} : -58.8 (s); **¹³C{¹H} NMR** (126 MHz, CDCl₃) δ_{C} : 88.4 (C(1)), 111.4 (CN), 112.6 (CN), 123.2 (q, $^1J_{\text{CF}}$ 274.1, CF₃), 127.0 (q, $^3J_{\text{CF}}$ 5.4, ArC(3)H), 128.6 (ArC(1)), 129.6 (q, $^2J_{\text{CF}}$ 31.1, ArC(2)), 129.8 (ArC(6)H), 132.8 (ArC(5)H), 133.1 (ArC(4)H), 156.7 (C(2)H); **HRMS** (*MALDI (no matrix)*⁺) C₁₁H₅N₂F₃Na [*M* + *Na*]⁺ found 245.0290, requires 245.0297 (-2.9 ppm).


2-(4-(Dimethylamino)benzylidene)malononitrile (34)



Following General Procedure A, 4-dimethylaminobenzaldehyde (0.75 g, 5.0 mmol), malononitrile (0.33 g, 5.0 mmol) and piperidine (0.043 g, 0.05 mL, 0.50 mmol) in EtOH (10 mL) gave the title compound as orange crystals (0.92 g, 92%). **mp** 170-172 °C {lit⁸ 180 °C}; **IR** ν_{max} (film) 2208 (C $\equiv$ N, nitrile), 1616, 1609, 1558, 1541, 1520, 1456, 1387, 1362, 1194, 1179,


816; **¹H NMR** (500 MHz, CDCl₃) δ_H: 3.17 (6H, s, CH₃), 6.72 – 6.77 (2H, m, ArC(3,5)H), 7.50 (1H, s, C(2)H), 7.81 – 7.87 (2H, m, ArC(2,6)H); **¹³C{¹H} NMR** (126 MHz, CDCl₃) δ_C: 40.1 (N(CH₃)₂), 71.7 (C(1)), 111.6 (ArC(3,5)H), 115.0 (CN), 116.1 (CN), 119.3 (ArC(1)), 133.8 (ArC(2,6)H), 154.3 (ArC(4)), 158.1 (C(2)H); **HRMS** (*EI*⁺) C₁₂H₁₁N₃ [*M*]⁺ found 197.0950, requires 197.0947 (+1.5 ppm).

(*E*)-2-(3-phenylallylidene)malononitrile (35)



Adapting the procedure of Chen and co-workers,⁹ cinnamaldehyde (1.26 mL, 10 mmol, 1.0 equiv.), malononitrile (0.66 g, 10 mmol, 1.0 equiv.) and K₂CO₃ (0.14 g, 1.0 mmol, 0.1 equiv.) were ground together rapidly in a mortar for 5 min. Once complete, the reaction mixture was dissolved in CH₂Cl₂, extracted with H₂O (x2) then dried over MgSO₄, filtered, and the solvent removed under reduced pressure to give the crude product as a yellow solid. The crude product was recrystallised from ethanol to give the title compound as yellow crystals (0.84 g, 47%). **mp** 124-126 °C (EtOH) {lit¹⁰ 128 °C}; **IR** ν_{max} (film) 3032 (C-H), 2222 (C≡N, nitrile), 1609, 1576, 1560, 1539, 1491, 1449, 1358, 1321, 1279, 1179, 1152, 976; **¹H NMR** (500 MHz, CDCl₃) δ_H: 7.24 – 7.35 (2H, m, C(3)H and C(4)H), 7.44 – 7.54 (3H, m, ArC(3,4,5)H), 7.60 – 7.66 (3H, m, ArC(2,6)H and C(2)H); **¹³C{¹H} NMR** (126 MHz, CDCl₃) δ_C: 82.9 (C(1)), 111.7 (CN), 113.6 (CN), 122.3 (C(3)H), 129.0 (ArC(2,6)H), 129.4 (ArC(3,5)H), 132.2 (ArC(4)H), 133.9 (ArC(1)), 150.6 (C(4)H), 160.2 (C(2)H); **HRMS** (*EI*⁺) C₁₂H₈N₂ [*M*]⁺ found 180.0682, requires 180.0682 (+0.0 ppm).

1-propylidenemalononitrile (36)




Following the procedure of McQuade and co-workers,¹¹ to a stirred solution of malononitrile (1.32 g, 20 mmol, 1.0 equiv.) and propionaldehyde (1.44 mL, 20 mmol, 1.0

equiv.) in CHCl_3 (1.0 M) was added slowly Al_2O_3 (activated basic, Brockmann I) (2.85 g, 28 mmol, 1.4 equiv.). After addition, the reaction mixture was stirred at RT for 1 h then the Al_2O_3 filtered off, washing with CH_2Cl_2 . The filtrate was concentrated under reduced pressure then the residue distilled to give the title compound as a colourless oil (1.48 g, 70%). $^1\text{H NMR}$ (500 MHz, CDCl_3) δ_{H} : 1.22 (3H, t, J 7.6, CH_3), 2.63 (2H, dq, J 7.6, 7.6, CH_2CH_3), 7.35 (1H, t, J 7.6, $\text{CH}=\text{C}$); ^{13}C $\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ_{C} : 12.0 (CH_3), 26.4 (CH_2CH_3), 89.5 ($\text{CH}=\text{C}$), 110.4 (CN), 112.1 (CN), 170.8 ($\text{CH}=\text{C}$).


Spectroscopic data in accordance with the literature.¹¹

7 Preparation of electron-deficient aryl esters

Ester **7** was available in the laboratory, previously prepared following the literature procedure.²




4-Nitrophenyl 2-(*p*-tolyl)acetate (**1**)



Following General Procedure B, Method B, 2-(*p*-tolyl)acetic acid (5.0 g, 34 mmol, 1.0 equiv.), EDCI·HCl (8.4 g, 44 mmol, 1.3 equiv.) and 4-nitrophenol (7.0 g, 50 mmol, 1.5 equiv.) in CH_2Cl_2 (0.6 M) for 24 h gave crude product which was purified by flash silica column chromatography (CH_2Cl_2 , R_f 0.71) to give the title compound as yellow-white crystals (6.9 g, 75%). mp 58-60 °C {Lit² 60-62 °C}; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ_{H} : 2.39 (3H, s, CH_3), 3.88 (2H, s, $\text{C}(2)\text{H}_2$), 7.19 – 7.25 (2H, m, $\text{Ar}^2\text{C}(3,5)\text{H}$), 7.25 – 7.32 (4H, m, $\text{Ar}^1\text{C}(2,6)\text{H}$ and $\text{Ar}^2\text{C}(2,6)\text{H}$), 8.23 – 8.30 (2H, m, $\text{Ar}^1\text{C}(3,5)\text{H}$).

Spectroscopic data in accordance with literature.²


3,5-Bis(trifluoromethyl)phenyl 2-(*p*-tolyl)acetate (6)



Following General Procedure B, Method A, 2-(*p*-tolyl)acetic acid (1.25 g, 8.4 mmol, 2.0 equiv.), EDCI·HCl (1.20 g, 6.3 mmol, 1.5 equiv.) and 3,5-bis(trifluoromethyl)phenol (0.96 g, 4.2 mmol, 1.0 equiv.) in CH₂Cl₂ (0.3 M) for 54 h gave crude product which was purified by flash silica column chromatography (CH₂Cl₂) to give the title compound as a colourless solid (1.36 g, 89%). **mp** 48-50 °C {Lit² 57-58 °C}; ¹H NMR (500 MHz, CDCl₃) δ_H: 2.39 (3H, s, CH₃), 3.89 (2H, s, C(2)H₂), 7.21 – 7.24 (2H, m, Ar²C(2,6)H), 7.27 – 7.30 (2H, m, Ar²C(3,5)H), 7.59 (2H, s, Ar¹C(2,6)H), 7.76 (1H, s, Ar¹C(4)H); ¹⁹F{¹H} NMR (470 MHz, CDCl₃) δ_F: -62.9 (s).

Spectroscopic data in accordance with literature.²


2,3,4,5,6-Pentafluorophenyl 2-(*p*-tolyl)acetate (8)



Following General Procedure B, Method B, 2-(*p*-tolyl)acetic acid (1.50 g, 10 mmol, 1.0 equiv.), EDCI·HCl (2.50 g, 13 mmol, 1.3 equiv.) and pentafluorophenol (2.76 g, 15 mmol, 1.5 equiv.) in CH₂Cl₂ (0.6 M) for 72 h gave crude product which was purified by flash silica column chromatography (Petrol:CH₂Cl₂ 1:1, R_f 0.71) to give the title compound as yellow-white crystals (1.86 g, 59%). **mp** 28-29 °C {Lit² 27-29 °C}; ¹H NMR (500 MHz, CDCl₃) δ_H: 2.38 (3H, s, CH₃), 3.95 (2H, s, C(2)H₂), 7.19 – 7.23 (2H, m, Ar²C(3,5)H), 7.25 – 7.28 (2H, m, Ar²C(2,6)H); ¹⁹F{¹H} NMR (376 MHz, CDCl₃) δ_F: -162.5 – -162.2 (m), -157.9 (t, *J* 21.7), -152.7 – -152.5 (m).

Spectroscopic data in accordance with literature.²


2,3,5,6-Tetrafluorophenyl 2-(*p*-tolyl)acetate (9)



Following General Procedure C, 2-(*p*-tolyl)acetic acid (10.1 g, 67.0 mmol, 2.0 equiv.), EDCI·HCl (9.63 g, 50.3 mmol, 1.5 equiv.) and 2,3,5,6-tetrafluorophenol (5.56 g, 33.5 mmol, 1.0 equiv.) in CH₂Cl₂ (0.3 M) for 240 h gave crude product which was purified by flash silica column chromatography (CH₂Cl₂, R_f 0.75) to give the title compound as a yellow-white solid (9.19 g, 92%). **mp** 28–30 °C {lit² 27–29 °C}; ¹H NMR (400 MHz, CDCl₃) δ_H: 2.38 (3H, s, CH₃), 3.96 (2H, s, C(2)H₂), 7.01 (1H, tt, *J* 9.9, 7.0, Ar¹C(4)H), 7.18 – 7.24 (2H, m, Ar²C(2,6)H), 7.25 – 7.31 (2H, m, Ar²C(3,5)H); ¹⁹F{¹H} NMR (376 MHz, CDCl₃) δ_F: -152.9 – -152.8 (m), -139.1 – -139.0 (m).


Spectroscopic data in accordance with literature.²

2,3,5,6-Tetrafluorophenyl 2-(4-methoxyphenyl)acetate (40)




Following General Procedure C, 2-(4-methoxyphenyl)acetic acid (3.32 g, 20 mmol, 2.0 equiv.), EDCI·HCl (2.88 g, 15 mmol, 1.5 equiv.) and 2,3,5,6-tetrafluorophenol (1.66 g, 10 mmol, 1.0 equiv.) in CH₂Cl₂ (0.3 M) for 72 h gave crude product which was purified by flash silica column chromatography (CH₂Cl₂, R_f 0.82) to give the title compound as a colourless solid (2.71 g, 86 %). **mp** 30–32 °C; **IR** ν_{max} (film) 1786 (C=O, ester), 1522, 1514, 1485, 1086; ¹H NMR (500 MHz, CDCl₃) δ_H: 3.84 (3H, s, OCH₃), 3.95 (2H, s, C(2)H₂), 6.93 – 6.97 (2H, m, Ar²C(3,5)H), 7.01 (1H, tt, *J* 10.0, 7.0, Ar¹C(4)H), 7.30 – 7.35 (2H, m, Ar²C(2,6)H); ¹⁹F{¹H} NMR (470 MHz, CDCl₃) δ_F: -152.9 – -152.8 (m), -139.1 – -139.0 (m); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ_C: 39.4 (C(2)H₂), 55.2 (OCH₃), 103.2 (t, *J* 22.8, Ar¹C(4)H), 114.2 (Ar²C(3,5)H), 124.2 (Ar²C(1)), 129.7 (tt, *J* 14.1, 3.9, Ar¹C(1)), 130.4 (Ar²C(2,6)H), 140.6 (m, Ar¹CF), 146.0 (m, Ar¹CF), 159.2 (Ar²C(4)), 167.8 (C(1)); **HRMS** (*EI*⁺) C₁₅H₁₀O₃F₄ [*M*]⁺ found 314.0572, requires 314.0561 (+3.7 ppm).

2,3,5,6-Tetrafluorophenyl 2-(4-(dimethylamino)phenyl)acetate (S12)



Following General Procedure C, 2-(4-(dimethylamino)phenyl)acetic acid (1.79 g, 10 mmol, 2.0 equiv.), EDCI·HCl (1.44 g, 7.5 mmol, 1.5 equiv.) and 2,3,5,6-tetrafluorophenol (0.83 g, 5.0 mmol, 1.0 equiv.) in CH₂Cl₂ (0.3 M) for 99 h gave crude product which was purified by flash silica column chromatography (Petrol:CH₂Cl₂ 1:1, R_f 0.53) to give the title compound as an off-white solid (1.45 g, 88%). **mp** 47–49 °C; **IR** ν_{max} (film) 1782 (C=O, ester), 1522, 1485, 1086; **¹H NMR** (400 MHz, CDCl₃) δ_{H} : 2.98 (6H, s, N(CH₃)₂), 3.90 (2H, s, C(2)H₂), 6.73 – 6.78 (2H, m, Ar²C(3,5)H), 6.99 (1H, tt, *J* 9.9, 7.0, Ar¹C(4)H), 7.22 – 7.27 (2H, m, Ar²C(2,6)H); **¹⁹F{¹H} NMR** (376 MHz, CDCl₃) δ_{F} : -152.9 – -152.7 (m), -139.3 – -139.1 (m); **¹³C{¹H} NMR** (126 MHz, CDCl₃) δ_{C} : 39.3 (C(2)H₂), 40.6 (CH₃), 103.1 (t, *J* 22.9, Ar¹C(4)H), 112.7 (Ar²C(3,5)H), 119.6 (Ar²C(1)), 129.8 – 130.1 (m, Ar¹C(1) and Ar²C(2,6)H), 140.7 (m, Ar¹CF), 146.0 (m, Ar¹CF), 150.0 (Ar²C(4)), 168.1 (C(1)); **HRMS** (*EL*⁺) C₁₆H₁₃O₂N₁F₄ [*M*]⁺ found 327.0883, requires 327.0877 (+1.7 ppm).


2,3,5,6-Tetrafluorophenyl 2-(thiophen-3-yl)acetate (S13)



Following General Procedure C, 2-(thiophen-3-yl)acetic acid (1.42 g, 10 mmol, 2.0 equiv.), EDCI·HCl (1.44 g, 7.5 mmol, 1.5 equiv.) and 2,3,5,6-tetrafluorophenol (0.83 g, 5.0 mmol, 1.0 equiv.) in CH₂Cl₂ (0.3 M) for 165 h gave crude product which was purified by flash silica column chromatography (CH₂Cl₂, R_f 0.80) to give the title compound as a yellow oil (1.36 g, 94 %). **IR** ν_{max} (film) 1786 (C=O, ester), 1522, 1485, 1092; **¹H NMR** (400 MHz, CDCl₃) δ_{H} : 4.05 (2H, s, C(2)H₂), 7.03 (1H, tt, *J* 9.9, 7.1, Ar¹C(4)H), 7.15 (1H, dd, *J* 5.0, 1.3, C(4')H), 7.30 – 7.33 (1H, m, C(2')H), 7.38 (1H, dd, *J* 5.0, 3.0, C(5')H); **¹⁹F{¹H} NMR** (376 MHz, CDCl₃) δ_{F} : -152.9 – -152.8 (m), -139.0 – -138.8 (m); **¹³C{¹H} NMR** (126 MHz, CDCl₃) δ_{C} : 34.7 (C(2)H₂), 103.3 (t, *J* 22.8, Ar¹C(4)H), 123.7 (C(2')H), 126.3 (C(5')H), 128.2 (C(4')H), 129.6 (tt, *J* 13.9, 3.7,


Ar¹C(1)), 131.6 (C(3)), 140.6 (m, Ar¹CF), 146.0 (m, Ar¹CF), 167.0 (C(1)); **HRMS** (EI^+) C₁₂H₆O₂F₄³²S₁ [M]⁺ found 290.0009, requires 290.0019 (-3.4 ppm).

2,3,5,6-Tetrafluorophenyl (*E*)-pent-3-enoate (S14)



Following General Procedure C, (*E*)-pent-3-enoic acid (1.02 mL, 10 mmol, 2.0 equiv.), EDCI·HCl (1.44 g, 7.5 mmol, 1.5 equiv.) and 2,3,5,6-tetrafluorophenol (0.83 g, 5 mmol, 1.0 equiv.) in CH₂Cl₂ (0.3 M) for 168 h gave crude product which was purified by flash silica column chromatography (CH₂Cl₂, R_f 0.77) to give the title compound as a colourless oil (1.03 g, 83%). **IR** ν_{max} (film) 3086 (C-H), 1790 (C=O, ester), 1522, 1485, 1179, 1086, 955; **¹H NMR** (400 MHz, CDCl₃) δ_H: 1.74 – 1.80 (3H, m, C(5)H₃), 3.38 – 3.42 (2H, m, C(2)H₂), 5.58 – 5.68 (1H, m, C(4)H), 5.71 – 5.82 (1H, m, C(3)H), 7.02 (1H, tt, *J* 9.9, 7.1, ArC(4)H); **¹⁹F{¹H} NMR** (376 MHz, CDCl₃) δ_F: -153.1 – -153.0 (m), -139.2 – -139.0 (m); **¹³C{¹H} NMR** (126 MHz, CDCl₃) δ_C: 18.0 (C(5)H₃), 37.0 (C(2)H₂), 103.2 (t, *J* 22.7, ArC(4)H), 120.7 (C(4)H), 129.5 – 129.9 (m, ArC(1)), 131.2 (C(3)H), 139.4 – 141.8 (m, ArCF), 146.0 (m, ArCF), 168.0 (C(1)); **HRMS** ($MALDI$ (no matrix)⁺) C₁₁H₈O₂F₄Na [$M + Na$]⁺ found 271.0345, requires 271.0353 (-3.0 ppm).


2,3,5,6-Tetrafluorophenyl 2-(*m*-tolyl)acetate (S15)



Following General Procedure C, 2-(*m*-tolyl)acetic acid (1.50 g, 10 mmol, 2.0 equiv.), EDCI·HCl (1.44 g, 7.5 mmol, 1.5 equiv.) and 2,3,5,6-tetrafluorophenol (0.83 g, 5 mmol, 1.0 equiv.) in CH₂Cl₂ (0.3 M) for 168 h gave crude product which was purified by flash silica column chromatography (CH₂Cl₂ : hexane 1:1, R_f 0.78) to give the title compound as a colourless oil (1.44 g, 97%). **IR** ν_{max} (film) 3080 (C-H), 1790 (C=O, ester), 1522, 1487, 1179, 1088, 955; **¹H NMR** (400 MHz, CDCl₃) δ_H: 2.41 (3H, s, CH₃), 3.98 (2H, s, C(2)H₂), 7.01 (1H, tt, *J* 9.9, 7.1, Ar¹C(4)H), 7.15 – 7.24 (3H, m, Ar²C(2,4,6)H), 7.28 – 7.33 (1H, m, Ar²C(5)H);


$^{19}\text{F}\{^1\text{H}\}$ NMR (376 MHz, CDCl_3) δ_{F} : -152.9 – -152.8 (m), -139.1 – -139.0 (m); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ_{C} : 21.4 (CH_3), 40.2 ($\text{C}(2)\text{H}_2$), 103.3 (t, J 22.8, $\text{Ar}^1\text{C}(4)\text{H}$), 126.3 ($\text{Ar}^2\text{C}(6)\text{H}$), 128.5 ($\text{Ar}^2\text{C}(4)\text{H}$), 128.8 ($\text{Ar}^2\text{C}(5)\text{H}$), 129.5 – 129.9 (m, $\text{Ar}^1\text{C}(1)$), 130.0 ($\text{Ar}^2\text{C}(2)\text{H}$), 132.1 ($\text{Ar}^2\text{C}(1)$), 138.6 ($\text{Ar}^2\text{C}(3)$), 140.6 (m, Ar^1CF), 146.0 (m, Ar^1CF), 167.6 ($\text{C}(1)$); HRMS (EI^+) $\text{C}_{15}\text{H}_{10}\text{O}_2\text{F}_4$ $[M]^+$ found 298.0606, requires 298.0611 (-1.7 ppm).

2,3,5,6-Tetrafluorophenyl 2-(*o*-tolyl)acetate (S16)



Following General Procedure C, 2-(*o*-tolyl)acetic acid (1.50 g, 10 mmol, 2.0 equiv.), EDCI·HCl (1.44 g, 7.5 mmol, 1.5 equiv.) and 2,3,5,6-tetrafluorophenol (0.83 g, 5 mmol, 1.0 equiv.) in CH_2Cl_2 (0.3 M) for 168 h gave crude product which was purified by flash silica column chromatography (CH_2Cl_2 : hexane 1:1, R_f 0.64) to give the title compound as a colourless solid (1.46 g, 98%). mp 54-56 °C; IR ν_{max} (film) 3078 (C-H), 1782 (C=O, ester), 1522, 1487, 1179, 1086, 955; ^1H NMR (400 MHz, CDCl_3) δ_{H} : 2.42 (3H, s, CH_3), 4.02 (2H, s, $\text{C}(2)\text{H}_2$), 7.01 (1H, tt, J 9.9, 7.1, $\text{Ar}^1\text{C}(4)\text{H}$), 7.21 – 7.29 (3H, m, $\text{Ar}^2\text{C}(3,4,5)\text{H}$), 7.30 – 7.36 (1H, m, $\text{Ar}^2\text{C}(6)\text{H}$); $^{19}\text{F}\{^1\text{H}\}$ NMR (376 MHz, CDCl_3) δ_{F} : -153.0 – -152.9 (m), -139.1 – -139.0 (m); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ_{C} : 19.4 (CH_3), 38.3 ($\text{C}(2)\text{H}_2$), 103.3 (t, J 22.7, $\text{Ar}^1\text{C}(4)\text{H}$), 126.4 ($\text{Ar}^2\text{C}(5)\text{H}$), 128.1 ($\text{Ar}^2\text{C}(4)\text{H}$), 129.5 – 129.9 (m, $\text{Ar}^1\text{C}(1)$), 130.3 ($\text{Ar}^2\text{C}(6)\text{H}$), 130.6 ($\text{Ar}^2\text{C}(3)\text{H}$), 130.8 ($\text{Ar}^2\text{C}(1)$), 137.0 ($\text{Ar}^2\text{C}(2)$), 139.5 – 141.8 (m, Ar^1CF), 146.0 (m, Ar^1CF), 167.4 ($\text{C}(1)$); HRMS (ESI^+) $\text{C}_{15}\text{H}_{10}\text{O}_2\text{F}_4\text{Na}$ $[M + \text{Na}]^+$ found 321.0512, requires 321.0509 (+0.9 ppm).

2,3,5,6-Tetrafluorophenyl propanoate (33)




Following General Procedure C, propanoic acid (1.49 mL, 20 mmol, 2.0 equiv.), EDCI·HCl (2.88 g, 15 mmol, 1.5 equiv.) and 2,3,5,6-tetrafluorophenol (1.66 g, 10 mmol, 1.0 equiv.) in CH_2Cl_2 (0.3 M) for 168 h gave crude product which was purified by flash silica column

chromatography (CH_2Cl_2 , R_f 0.75) to give the title compound as a colourless oil (1.37 g, 62%). **IR** ν_{max} (film) 3088 (C-H), 1786 (C=O, ester), 1524, 1489, 1179, 1111, 1082, 953; **^1H NMR** (400 MHz, CDCl_3) δ_{H} : 1.33 (3H, t, J 7.5, CH_2CH_3), 2.73 (2H, q, J 7.5, CH_2CH_3), 7.01 (1H, tt, J 9.9, 7.1, ArC(4)H); **$^{19}\text{F}\{^1\text{H}\}$ NMR** (376 MHz, CDCl_3) δ_{F} : -153.3 – -153.2 (m), -139.3 – -139.1 (m); **$^{13}\text{C}\{^1\text{H}\}$ NMR** (126 MHz, CDCl_3) δ_{C} : 8.9 (CH_2CH_3), 26.9 (CH_2CH_3), 103.1 (t, J 22.8, ArC(4)H), 129.5 – 131.1 (m, ArC(1)), 139.4 – 141.9 (m, ArCF), 146.0 (m, ArCF), 170.3 (C(1)); **HRMS** (ESI^-) $\text{C}_9\text{H}_5\text{O}_2\text{F}_4$ $[M - H]^-$ found 221.0232, requires 221.0231 (+0.5 ppm).

8 Ester screen products

(2*R*,3*S*)-4-Nitrophenyl 4,4-dicyano-3-phenyl-2-(*p*-tolyl)butanoate (**4**) and (2*R*,3*R*)-4-Nitrophenyl 4,4-dicyano-3-phenyl-2-(*p*-tolyl)butanoate (**5**)




Following General Procedure D, 4-nitrophenyl 2-(*p*-tolyl)acetate **1** (203 mg, 0.75 mmol, 1.5 eq) gave crude product that was purified by flash silica column chromatography (Petrol:CH₂Cl₂ 1:1 to 1:3) to yield the combined *anti* and *syn* diastereoisomers (47:53 dr) (124 mg, 58%) as an inseparable mixture as a colourless solid. **mp** 54-56 °C; $[\alpha]_D^{20}$ -105.9 (*c* 1.4 in CHCl₃); **IR** $\nu_{\max}$ (film) 2922 (C-H), 1755 (C=O, ester), 1526, 1489, 1346, 1204, 1126, 756; **HRMS** (*El*⁺) C₂₅H₁₉O₄N₃Na [*M* + *Na*]⁺ found 448.1259, requires 448.1268 (-2.0 ppm).

Data for anti-4: Chiral HPLC analysis, Chiralcel OD-H (97:3 *n*-hexane : IPA, flow rate 1.5 mLmin⁻¹, 211 nm, 40 °C) *t*_R (2*R*,3*S*) 27.7 min, *t*_R (2*S*,3*R*) 31.3 min, 79:21 er; **¹H NMR** (400 MHz, CDCl₃) δ_{H} : 2.45 (3H, s, CH₃), 3.75 (1H, d, *J* 4.0, C(4)*H*), 3.97 (1H, dd, *J* 12.2, 4.0, C(3)*H*), 4.57 (1H, d, *J* 12.2, C(2)*H*), 6.69 – 6.74 (2H, m, Ar¹C(2,6)*H*), 7.34 – 7.40 (2H, m, Ar²C(3,5)*H*), 7.51 – 7.58 (5H, m, Ar²C(2,6)*H* and Ar³C(3,4,5)*H*), 7.63 – 7.69 (2H, m, Ar³C(2,6)*H*), 8.09 – 8.16 (2H, m, Ar¹C(3,5)*H*); **¹³C{¹H} NMR** (126 MHz, CDCl₃) δ_{C} : 21.3 (CH₃), 27.7 (C(4)*H*), 49.4 (C(3)*H*), 53.6 (C(2)*H*), 110.7 (CN), 111.3 (CN), 122.0 (Ar¹C(2,6)*H*), 125.2 (Ar¹C(3,5)*H*), 128.1 (Ar³C(4)*H*), 128.6 (Ar³C(2,6)*H*), 129.5 (Ar³C(3,5)*H*), 129.8 (Ar²C(1)), 129.9 (Ar²C(2,6)*H*), 131.0 (Ar²C(3,5)*H*), 134.1 (Ar³C(1)), 140.2 (Ar²C(4)), 145.6 (Ar¹C(1)), 154.6 (Ar¹C(4)), 168.5 (C(1)).

Data for syn-5: Chiral HPLC analysis, Chiralcel OD-H (97:3 *n*-hexane : IPA, flow rate 1.5 mLmin⁻¹, 211 nm, 40 °C) *t*_R (2*S*,3*S*) 43.2 min, *t*_R (2*R*,3*R*) 62.1 min, 93:7 er; **¹H NMR** (400 MHz, CDCl₃) δ_{H} : 2.27 (3H, s, CH₃), 4.01 (1H, dd, *J* 11.4, 5.4, C(3)*H*), 4.53 (1H, d, *J* 11.4, C(2)*H*), 4.72 (1H, d, *J* 5.4, C(4)*H*), 7.03 – 7.10 (4H, m, Ar²C(2,3,5,6)*H*), 7.17 – 7.22 (2H, m, Ar¹C(2,6)*H*), 7.26 – 7.34 (5H, m, Ar³(2,6)*H* and Ar³C(3,4,5)*H*), 8.24 – 8.31 (2H, m, Ar¹C(3,5)*H*); **¹³C{¹H} NMR** (126 MHz, CDCl₃) δ_{C} : 21.1 (CH₃), 28.0 (C(4)*H*), 47.8 (C(3)*H*), 53.0 (C(2)*H*), 111.2 (CN), 111.5 (CN), 122.2 (Ar¹C(2,6)*H*), 125.3 (Ar¹C(3,5)*H*), 128.2 (Ar²C(2,6)*H*), 128.6 (Ar³C(2,6)*H*), 129.1 (Ar³C(3,5)*H*), 129.2 (Ar³C(4)*H*), 129.9 (Ar²C(3,5)*H*),

130.6 (Ar²C(1)), 133.6 (Ar³C(1)), 138.6 (Ar²C(4)), 145.8 (Ar¹C(1)), 154.7 (Ar¹C(4)), 170.5 (C(1)).

(2*R*,3*S*)-3,5-Bis(trifluoromethyl)phenyl 4,4-dicyano-3-phenyl-2-(*p*-tolyl)butanoate (10) and (2*R*,3*R*)-3,5-Bis(trifluoromethyl)phenyl 4,4-dicyano-3-phenyl-2-(*p*-tolyl)butanoate (11)




Following General Procedure D, 3,5-bis(trifluoromethyl)phenyl 2-(*p*-tolyl)acetate **6** (272 mg, 0.75 mmol, 1.5 eq) gave crude product that was purified by flash silica column chromatography (Petrol:Acetone 98:2 to 80:20) to yield the combined *anti* and *syn* diastereoisomers (52:48 dr) (125 mg, 48%) as an inseparable mixture as a colourless glass; $[\alpha]_D^{20}$ -73.3 (*c* 1.4 in CHCl₃); **IR** $\nu_{\max}$ (film) 1761 (C=O, ester), 1369, 1279, 1179, 1136; **HRMS** (El^+) C₂₇H₁₈O₂N₂F₆Na [$M + Na$]⁺ found 539.1155, requires 539.1165 (-1.8 ppm).

Data for anti-10: Chiral HPLC analysis, Chiralcel OD-H (99.5:0.5 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*R*,3*S*) 32.6 min, *t*_R (2*S*,3*R*) 39.8 min, 87:13 er; **¹H NMR** (500 MHz, CDCl₃) δ_H : 2.46 (3H, s, CH₃), 3.75 (1H, d, *J* 4.1, C(4)*H*), 3.95 (1H, dd, *J* 12.2, 4.1, C(3)*H*), 4.55 (1H, d, *J* 12.2, C(2)*H*), 7.35 – 7.40 (2H, m, Ar²C(3,5)*H*), 7.50 (2H, s, Ar¹C(2,6)*H*), 7.53 – 7.59 (5H, m, Ar²C(2,6)*H* and Ar³C(3,4,5)*H*), 7.64 – 7.70 (2H, m, Ar³C(2,6)*H*), 7.80 (1H, s, Ar¹C(4)*H*); **¹⁹F{¹H} NMR** (470 MHz, CDCl₃) δ_F : -69.2 (s); **¹³C{¹H} NMR** (126 MHz, CDCl₃) δ_C : 21.2 (CH₃), 27.6 (C(4)*H*), 49.6 (C(3)*H*), 53.6 (C(2)*H*), 110.7 (CN), 111.5 (CN), 120.2 – 120.4 (m, Ar¹C(4)*H*), 121.9 – 122.2 (m, Ar¹C(2,6)*H*), 122.5 (q, *J* 273, CF₃), 128.6 (Ar²C(2,6)*H*), 128.7 (Ar³C(2,6)*H*), 130.0 (Ar³C(3,5)*H*), 130.1 (Ar³C(4)*H*), 130.4 (Ar²C(1)), 131.0 (Ar²C(3,5)*H*), 132.9 (q, *J* 34.4, Ar¹C(3,5)), 134.0 (Ar³C(1)), 140.3 (Ar²C(4)), 150.6 (Ar¹C(1)), 168.8 (C(1)).

Data for syn-11: Chiral HPLC analysis, Chiralcel OD-H (99.5:0.5 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*S*,3*S*) 24.2 min, *t*_R (2*R*,3*R*) 26.9 min, 97:3 er; **¹H NMR** (500 MHz, CDCl₃) (*selected*) δ_H : 2.28 (3H, s, CH₃), 4.00 (1H, dd, *J* 11.4, 5.4, C(3)*H*), 4.52 (1H, d, *J* 11.4, C(2)*H*), 4.71 (1H, d, *J* 5.4, C(4)*H*), 6.92 (2H, s, Ar¹C(2,6)*H*), 7.03 – 7.10 (4H, m,

Ar²C(2,3,5,6)H), 7.25 – 7.35 (5H, m, Ar³(2,3,4,5,6)H); ¹⁹F{¹H} NMR (470 MHz, CDCl₃) δ_F: -63.1 (s); ¹³C{¹H} NMR (126 MHz, CDCl₃) (*selected*) δ_C: 21.1 (CH₃), 28.0 (C(4)H), 47.9 (C(3)H), 53.0 (C(2)H), 111.2 (CN), 111.2 (CN), 120.0 – 120.2 (m, Ar¹C(4)H), 122.5 (q, *J* 273, CF₃), 128.2 (Ar²C(2,6)H), 129.1(Ar³C(3,5)H), 129.2 (Ar³C(4)H), 129.5 (Ar²C(1)), 133.6 (Ar³C(1)), 138.7 (Ar²C(4)), 150.4 (Ar¹C(1)), 170.5 (C(1)).

(2*R*,3*S*)-Perfluorophenyl 4,4-dicyano-3-phenyl-2-(*p*-tolyl)butanoate (12) and (2*R*,3*R*)-Perfluorophenyl 4,4-dicyano-3-phenyl-2-(*p*-tolyl)butanoate (13)



Following General Procedure D, 2,3,4,5,6-pentafluorophenyl 2-(*p*-tolyl)acetate **8** (237 mg, 0.75 mmol, 1.5 eq) gave crude product that was purified by flash silica column chromatography (Petrol:Acetone 95:5 to 80:20) to yield the combined *anti* and *syn* diastereoisomers (78:22 dr) (149 mg, 63%) as an inseparable mixture as a colourless solid.

mp 138–140 °C; [α]_D²⁰ -68.0 (*c* 2.3 in CHCl₃); **IR** $\nu_{\max}$ (film) 1780 (C=O, ester), 1520, 1109, 997; **HRMS** (*ESI*⁺) C₂₅H₁₅O₂N₂F₅Na [*M* + *Na*]⁺ found 493.0942, requires 493.0946 (-0.8 ppm).


Data for major diastereoisomer anti-12: Chiral HPLC analysis, Chiralcel OD-H (99.5:0.5 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*S*,3*R*) 39.2 min, *t*_R (2*R*,3*S*) 42.6 min, 89:11 er; ¹H NMR (500 MHz, CDCl₃) δ_H: 2.45 (3H, s, CH₃), 3.73 (1H, d, *J* 3.9, C(4)H), 3.97 (1H, dd, *J* 12.2, 3.9, C(3)H), 4.67 (1H, d, *J* 12.2, C(2)H), 7.34 – 7.38 (2H, m, Ar²C(3,5)H), 7.47 – 7.55 (5H, m, Ar²C(2,6)H and Ar³C(3,4,5)H), 7.60 – 7.64 (2H, m, Ar³C(2,6)H); ¹⁹F{¹H} NMR (470 MHz, CDCl₃) δ_F: -162.1 – -161.9 (m), -157.2 (t, *J* 21.8), -152.5 – -152.4 (m); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ_C: 21.3 (CH₃), 27.8 (C(4)H), 48.9 (C(3)H), 52.8 (C(2)H), 110.6 (CN), 111.3 (CN), 124.0 – 124.7 (m, Ar¹C(1)), 128.0 (Ar³C(4)H), 128.3 (Ar³C(2,6)H), 129.4 (Ar²C(1)), 129.5 (Ar³C(3,5)H), 129.9 (Ar²C(2,6)H), 131.0 (Ar²C(3,5)H), 133.7 (Ar³C(1)), 136.4 – 138.7 (m, Ar¹CF), 138.7 – 140.9 (m, Ar¹CF), 139.6 – 141.9 (m, Ar¹CF), 140.4 (Ar²C(4)), 166.8 (C(1)).

Data for minor diastereoisomer syn-13: Chiral HPLC analysis, Chiralcel OD-H (99.5:0.5 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*S*,3*S*) 33.2 min, *t*_R (2*R*,3*R*) 57.5 min,

93:7 er; ^1H NMR (500 MHz, CDCl_3) (*selected*) δ_{H} : 2.27 (3H, s, CH_3), 4.62 (1H, d, J 11.3, C(2)H), 7.02–7.07 (4H, m, $\text{Ar}^2\text{C}(2,3,5,6)\text{H}$), 7.26–7.34 (5H, m, $\text{Ar}^3(2,6)\text{H}$ and $\text{Ar}^3\text{C}(3,4,5)\text{H}$); $^{19}\text{F}\{^1\text{H}\}$ NMR (470 MHz, CDCl_3) δ_{F} : -161.6 – -161.4 (m), -156.5 (t, J 21.6), -152.3 – -152.1 (m); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) (*selected*) δ_{C} : 21.1 (CH_3), 27.8 (C(4)H), 47.9 (C(3)H), 52.3 (C(2)H), 111.0 (CN), 111.1 (CN), 128.2 ($\text{Ar}^2\text{C}(2,6)\text{H}$), 128.6 ($\text{Ar}^3\text{C}(2,6)\text{H}$), 129.1 ($\text{Ar}^3\text{C}(3,5)\text{H}$), 129.3 ($\text{Ar}^3\text{C}(4)\text{H}$), 129.8 ($\text{Ar}^2\text{C}(1)$), 129.9 ($\text{Ar}^2\text{C}(3,5)\text{H}$), 133.1 ($\text{Ar}^3\text{C}(1)$), 138.8 ($\text{Ar}^2\text{C}(4)$), 169.1 (C(1)).


9 Isothiourea catalysis products

(2*R*,3*S*)-2,3,5,6-tetrafluorophenyl 4,4-dicyano-3-phenyl-2-(*p*-tolyl)butanoate (**14**)



Following General Procedure E, 2,3,5,6-tetrafluorophenyl 2-(*p*-tolyl)acetate **9** (224 mg, 0.75 mmol, 1.5 eq), 2-benzylidene malononitrile **2** (78 mg, 0.50 mmol, 1.0 eq), and (4*bR*,11*aS*)-fused-BTM **19** (6.6 mg, 0.025 mmol, 5 mol%) in CPME (1.0 M) gave crude product that was purified by flash silica chromatography (hexane:acetone 90:10 to 80:20, R_F 0.10 at 90:10) to give the combined *anti* and *syn* diastereoisomers (95:5 dr) (208 mg, 92%) as an inseparable mixture. The mixture of diastereoisomers was recrystallized from hexane/ CH_2Cl_2 to give the title compound (174 mg, 77%, single major diastereoisomer) as a colourless solid. **mp** 179-181 °C; $[\alpha]_D^{20}$ -64.6 (c 2.0 in CHCl_3); **Chiral HPLC analysis**, Chiralcel OD-H (99:1 *n*-hexane : IPA, flow rate 1.5 mLmin⁻¹, 211 nm, 30 °C) t_R (2*S*,3*R*) 24.4 min, t_R (2*R*,3*S*) 29.4 min, >99:1 er; **IR** ν_{max} (film) 2907 (C-H), 1788 (C=O, ester), 1524, 1489, 1180, 1117, 1088, 1070, 953; **¹H NMR** (400 MHz, CDCl_3) δ_H : 2.45 (3H, s, CH_3), 3.75 (1H, d, J 4.0, C(4)*H*), 3.99 (1H, dd, J 12.2, 4.0, C(3)*H*), 4.69 (1H, d, J 12.2, C(2)*H*), 6.93 (1H, tt, J 9.9, 7.0 Ar¹C(4)*H*), 7.33 – 7.39 (2H, m, Ar²C(3,5)*H*), 7.47 – 7.57 (5H, m, Ar²C(2,6)*H* and Ar³C(3,4,5)*H*), 7.61 – 7.67 (2H, m, Ar³C(2,6)*H*); **¹⁹F{¹H} NMR** (376 MHz, CDCl_3) δ_F : -152.8 – -152.6 (m), -138.8 – -138.6 (m); **¹³C{¹H} NMR** (126 MHz, CDCl_3) δ_C : 21.2 (CH_3), 27.8 (C(4)*H*), 48.9 (C(3)*H*), 52.9 (C(2)*H*), 103.5 (t, J 22.7, Ar¹C(4)*H*), 110.7 (CN), 111.3 (CN), 128.1 (Ar³C(4)*H*), 128.3 (Ar³C(2,6)*H*), 128.6 – 129.1 (Ar¹C(1)), 129.5 (Ar³C(3,5)*H*), 129.9 (Ar²C(2,6)*H*), 129.9 (Ar²C(1)), 131.0 (Ar²C(3,5)*H*), 133.7 (Ar³C(1)), 139.0 – 141.4 (m, Ar¹CF), 140.3 (Ar²C(4)), 144.6 – 147.0 (m, Ar¹CF), 166.7 (C(1)). **HRMS** (ESI^+) $\text{C}_{25}\text{H}_{16}\text{O}_2\text{N}_2\text{F}_4\text{Na}$ $[M + Na]^+$ found 475.1023, requires 475.1040 (-3.6 ppm).

(2*R*,3*S*)-2,3,5,6-tetrafluorophenyl 4,4-dicyano-2-(4-methoxyphenyl)-3-phenylbutanoate (20) and (2*R*,3*R*)-2,3,5,6-tetrafluorophenyl 4,4-dicyano-2-(4-methoxyphenyl)-3-phenylbutanoate (S17)




Following General Procedure E, 2,3,5,6-tetrafluorophenyl 2-(4-methoxyphenyl)acetate **40** (236 mg, 0.75 mmol, 1.5 eq), 2-benzylidenemalononitrile **2** (78 mg, 0.50 mmol, 1.0 eq), and (4*bR*,11*aS*)-fused-BTM **19** (6.6 mg, 0.025 mmol, 5 mol%) in CPME (1.0 M) gave crude product (85:15 dr) that was purified by flash silica column chromatography (hexane:Et₂O 90:10 to 70:30) to give:

Anti-**20** (152 mg, 65%) as a colourless solid. **mp** 52–54 °C; $[\alpha]_D^{20}$ -65.9 (*c* 2.1 in CHCl₃); **Chiral HPLC analysis**, Chiralcel OD-H (90:10 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*S*,3*R*) 19.3 min, *t*_R (2*R*,3*S*) 22.7 min, 99:1 er; **IR** *v*_{max} (film) 2903 (C-H), 1778 (C=O, ester), 1609, 1524, 1512, 1487, 1254, 1179, 1109, 957; **¹H NMR** (400 MHz, CDCl₃) δ _H: 3.77 (1H, d, *J* 4.0, C(4)*H*), 3.89 (3H, s, OCH₃), 3.97 (1H, dd, *J* 12.2, 4.0, C(3)*H*), 4.67 (1H, d, *J* 12.2, C(2)*H*), 6.93 (1H, tt, *J* 9.9, 7.0, Ar¹C(4)*H*), 7.03 – 7.10 (2H, m, Ar²C(3,5)*H*), 7.46 – 7.59 (5H, m, Ar²C(2,6)*H* and Ar³C(3,4,5)*H*), 7.60 – 7.66 (2H, m, Ar³C(2,6)*H*); **¹⁹F{¹H} NMR** (376 MHz, CDCl₃) δ _F: -152.8 – 152.7 (m), -138.8 – -138.6 (m); **¹³C{¹H} NMR** (126 MHz, CDCl₃) δ _C: 27.8 (C(4)*H*), 48.9 (C(3)*H*), 52.5 (C(2)*H*), 55.5 (OCH₃), 103.6 (t, *J* 22.7, Ar¹C(4)*H*), 110.7 (CN), 111.4 (CN), 115.6 (Ar²C(3,5)*H*), 124.2 (Ar²C(1)), 128.3 (Ar³C(2,6)*H*), 128.7 – 129.1 (m, Ar¹C(1)), 129.5 (Ar³C(3,5)*H* and Ar²C(2,6)*H*), 129.9 (Ar³C(4)*H*), 133.8 (Ar³C(1)), 139.1 – 141.4 (m, Ar¹CF), 144.7 – 147.0 (m, Ar¹CF), 160.8 (Ar²C(4)), 166.8 (C(1)); **HRMS** (*ESI*⁺) C₂₅H₁₆O₃N₂F₄Na [*M* + *Na*]⁺ found 491.1013, requires 491.0989 (+4.9 ppm).

Syn-**S17** (30 mg, 13%) as a colourless glass. $[\alpha]_D^{20}$ -151.2 (*c* 0.7 in CHCl₃); **Chiral HPLC analysis**, Chiralcel OD-H (90:10 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*S*,3*S*) 11.7 min, *t*_R (2*R*,3*R*) 16.1 min, 96:4 er; **IR** *v*_{max} (film) 2918 (C-H), 1771 (C=O, ester), 1526, 1514, 1487, 1256, 1180, 957; **¹H NMR** (400 MHz, CDCl₃) δ _H: 3.75 (3H, s, OCH₃), 3.99

(1H, dd, *J* 11.3, 5.2, C(3)*H*), 4.62 (1H, d, *J* 11.3, C(2)*H*), 4.64 (1H, d, *J* 5.2, C(4)*H*), 6.73 – 6.80 (2H, m, Ar²C(3,5)*H*), 7.00 – 7.13 (3H, m, Ar¹C(4)*H* and Ar²C(2,6)*H*), 7.26 – 7.36 (5H, m, Ar³C(2,3,4,5,6)*H*); ¹⁹F{¹H} NMR (376 MHz, CDCl₃) δ_F: -152.5 – 152.4 (m), -138.3 – -138.1 (m); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ_C: 27.8 (C(4)*H*), 48.0 (C(3)*H*), 51.9 (C(2)*H*), 55.2 (OCH₃), 103.9 (t, *J* 22.6, Ar¹C(4)*H*), 111.0 (CN), 111.2 (CN), 114.5 (Ar²C(3,5)*H*), 124.8 (Ar²C(1)), 128.6 (Ar³C(2,6)*H*), 128.9 – 129.0 (m, Ar¹C(1)), 129.1 (Ar²C(2,6)*H*), 129.3 (Ar³C(4)*H*), 129.6 (Ar³C(3,5)*H*), 133.1 (Ar³C(1)), 139.1 – 141.5 (m, Ar¹CF), 144.8 – 147.2 (m, Ar¹CF), 159.6 (Ar²C(4)), 169.0 (C(1)); HRMS (*ESI*⁺) C₂₅H₁₆O₃N₂F₄Na [*M* + *Na*]⁺ found 491.0999, requires 491.0989 (+2.0 ppm).


(2*R*,3*S*)-2,3,5,6-tetrafluorophenyl 4,4-dicyano-2-(4-(dimethylamino)phenyl)-3-phenylbutanoate (21)



Following General Procedure E, 2,3,5,6-tetrafluorophenyl 2-(4-dimethylamino)phenyl acetate **S12** (245 mg, 0.75 mmol, 1.5 eq), 2-benzylidenemalononitrile **2** (78 mg, 0.50 mmol, 1.0 eq), and (4*bR*,11*aS*)-fused-BTM **19** (6.6 mg, 0.025 mmol, 5 mol%) in CPME (0.5 M) gave crude product (90:10 dr) that was purified by flash silica chromatography (hexane:Et₂O 90:10 to 70:30, *R*_F 0.24 at 70:30) to give the title compound as a colourless solid (166 mg, single diastereoisomer, 69%). mp 60–62 °C; [*α*]_D²⁰ -94.0 (*c* 2.0 in CHCl₃); **Chiral HPLC analysis**, Chiralcel AD-H (90:10 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*R*,3*S*) 11.3 min, *t*_R (2*S*,3*R*) 14.7 min, 99:1 er; **IR** *v*_{max} (film) 2897 (C-H), 1778 (C=O, ester), 1612, 1524, 1487, 1179, 1109, 957; ¹H NMR (400 MHz, CDCl₃) δ_H: 3.05 (6H, s, N(CH₃)₂), 3.82 (1H, d, *J* 3.9, C(4)*H*), 3.94 (1H, dd, *J* 12.2, 3.9, C(3)*H*), 4.59 (1H, d, *J* 12.2, C(2)*H*), 6.79 – 6.84 (2H, m, Ar²C(3,5)*H*), 6.91 (1H, tt, *J* 9.9, 7.0, Ar¹C(4)*H*), 7.42 – 7.47 (2H, m, Ar²C(2,6)*H*), 7.48 – 7.55 (3H, m, Ar³C(3,4,5)*H*), 7.60 – 7.65 (2H, m, Ar³C(2,6)*H*); ¹⁹F{¹H} NMR (376 MHz, CDCl₃) δ_F: -152.7 – 152.5 (m), -139.0 – -138.8 (m); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ_C: 27.8 (C(4)*H*), 40.2 (N(CH₃)₂), 49.1 (C(3)*H*), 52.4 (C(2)*H*), 103.4 (t, *J* 22.8, Ar¹C(4)*H*), 110.8 (CN),

111.6 (CN), 113.2 (Ar²C(3,5)), 118.9 (Ar²C(1)), 128.3 (Ar³C(2,6)), 128.8 – 129.2 (m, Ar²C(2,6) and Ar¹C(1)), 129.4 (Ar³C(3,5)), 129.7 (Ar³C(4)), 134.0 (Ar³C(1)), 139.0 – 141.5 (m, Ar¹CF), 144.6 – 147.0 (m, Ar¹CF), 151.2 (Ar²C(4)), 167.0 (C(1)); **HRMS** (*ESI*⁺) C₂₆H₂₀O₂N₃F₄ [*M* + *H*]⁺ found 482.1485, requires 482.1486 (-0.2 ppm).

(2*R*,3*S*)-2,3,5,6-tetrafluorophenyl 4,4-dicyano-3-phenyl-2-(*m*-tolyl)butanoate (22) and (2*R*,3*R*)- 2,3,5,6-tetrafluorophenyl 4,4-dicyano-3-phenyl-2-(*m*-tolyl)butanoate (S18)



Following General Procedure E, 2,3,5,6-tetrafluorophenyl 2-(*m*-tolyl)acetate **S15** (224 mg, 0.75 mmol, 1.5 eq), 2-benzylidene malononitrile **2** (78 mg, 0.50 mmol, 1.0 eq), and (4*bR*,11*aS*)-fused-BTM **19** (6.6 mg, 0.025 mmol, 5 mol%) in CPME (1.0 M) gave crude product (90:10 dr) that was purified by flash silica chromatography (hexane:acetone 90:10, *R_F* 0.13) to give a mixture of diastereoisomers (90:10 dr). The diastereoisomers were then separated by flash silica column chromatography (hexane:Et₂O 90:10 to 80:20) to give:


Anti-**22** (130 mg, 58%) as a colourless solid. **mp** 125–127 °C; [*α*]_D²⁰ -61.7 (*c* 1.2 in CHCl₃);

Chiral HPLC analysis, Chiralpak IA (97:3 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t_R* (2*R*,3*S*) 10.1 min, *t_R* (2*S*,3*R*) 14.6 min, 99:1 er; **IR** *v*_{max} (film) 1780 (C=O, ester), 1526, 1487, 1113; **¹H NMR** (400 MHz, CDCl₃) *δ*_H: 2.48 (3H, s, CH₃), 3.74 (1H, d, *J* 3.9, C(4)*H*), 3.99 (1H, dd, *J* 12.2, 3.9, C(3)*H*), 4.68 (1H, d, *J* 12.2, C(2)*H*), 6.93 (1H, tt, *J* 9.9, 7.0, Ar¹C(4)*H*), 7.31 – 7.37 (1H, m, Ar²C(4)*H*), 7.42 – 7.46 (3H, m, Ar²C(2,5,6)*H*), 7.49 – 7.56 (3H, m, Ar³C(3,4,5)*H*), 7.61 – 7.66 (2H, m, Ar³C(2,6)*H*); **¹⁹F{¹H} NMR** (376 MHz, CDCl₃) *δ*_F: -152.7 – -152.6 (m), -138.8 – -138.6 (m); **¹³C{¹H} NMR** (126 MHz, CDCl₃) *δ*_C: 21.5 (CH₃), 27.9

(C(4)H), 48.9 (C(3)H), 53.2 (C(2)H), 103.6 (t, J 22.7, Ar¹C(4)H), 110.7 (CN), 111.3 (CN), 125.3 (Ar²C(6)H), 128.3 (Ar³C(2,6)H), 128.5 – 129.1 (m, Ar²C(2)H and Ar¹C(1)), 129.5 (Ar³C(3,5)H), 129.9 (Ar³C(4)H), 130.1 (Ar²C(5)H), 130.9 (Ar²C(4)H), 132.5 (Ar²C(1)), 133.7 (Ar³C(1)), 139.1 – 141.3 (m, Ar¹CF), 140.4 (Ar²C(3)), 144.6 – 147.0 (m, Ar¹CF), 166.6 (C(1)); **HRMS** (EI^+) C₂₅H₁₆O₂N₂F₄ [M]⁺ found 452.1133, requires 452.1142 (-2.0 ppm).

Syn-S18 (15 mg, 7%) as a colourless glass. $[\alpha]_D^{20}$ -116.0 (c 0.3 in CHCl₃); **Chiral HPLC analysis**, Chiralpak AD-H (97:3 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) t_R (2*R*,3*R*) 10.8 min, t_R (2*S*,3*S*) 15.8 min, 91:9 er; **IR** ν_{max} (film) 1771 (C=O, ester), 1526, 1487, 1130; **¹H NMR** (400 MHz, CDCl₃) δ_H : 2.26 (3H, s, CH₃), 4.01 (1H, dd, J 11.3, 5.2, C(3)H), 4.62 (1H, d, J 11.3, C(2)H), 4.68 (1H, d, J 5.2, C(4)H), 6.94 – 7.16 (5H, m, Ar²C(2,4,5,6)H and Ar¹C(4)H), 7.26 – 7.36 (5H, m, Ar³C(2,3,4,5,6)H); **¹⁹F{¹H} NMR** (376 MHz, CDCl₃) δ_F : -152.5 – -152.4 (m), -138.2 – -138.1 (m); **¹³C{¹H} NMR** (126 MHz, CDCl₃) δ_C : 21.3 (CH₃), 27.8 (C(4)H), 48.0 (C(3)H), 52.6 (C(2)H), 103.9 (t, J 22.7, Ar¹C(4)H), 111.1 (CN), 111.2 (CN), 125.5 (Ar²C(6)H), 128.6 (Ar³C(2,6)H), 128.8 – 129.0 (m, Ar²C(2)H and Ar¹C(1)), 129.0 – 129.1 (m, Ar³C(3,4,5)H), 129.3 (Ar²C(5)H), 129.5 (Ar²C(4)H), 132.8 (Ar²C(1)), 133.1 (Ar³C(1)), 138.9 (Ar²C(3)), 139.2 – 141.5 (m, Ar¹CF), 144.8 – 147.2 (m, Ar¹CF), 168.9 (C(1)); **HRMS** (EI^+) C₂₅H₁₆O₂N₂F₄ [M]⁺ found 452.1139, requires 452.1142 (-0.7 ppm).

(2*R*,3*S*)-2,3,5,6-tetrafluorophenyl 4,4-dicyano-3-phenyl-2-(*o*-tolyl)butanoate (23) and (2*R*,3*R*)-2,3,5,6-tetrafluorophenyl 4,4-dicyano-3-phenyl-2-(*o*-tolyl)butanoate (S19)




Following General Procedure E, 2,3,5,6-tetrafluorophenyl 2-(*o*-tolyl)acetate **S16** (224 mg, 0.75 mmol, 1.5 eq), 2-benzylidene malononitrile **2** (78 mg, 0.50 mmol, 1.0 eq), and (4*bR*,11*aS*)-fused-BTM **19** (6.6 mg, 0.025 mmol, 5 mol%) in CPME (1.0 M) gave crude product that was purified by flash silica chromatography (hexane:acetone 90:10, R_F 0.17)

to give a mixture of diastereoisomers (80:20 dr). The diastereoisomers were then separated by flash silica column chromatography (hexane:Et₂O 80:20) to give:

Anti-**23** (72 mg, 32%) as a colourless solid. **mp** 93–95 °C; $[\alpha]_D^{20}$ -38.3 (*c* 1.2 in CHCl₃); **Chiral HPLC analysis**, Chiralcel OD-H (99.5:0.5 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t_R* (2*S*,3*R*) 40.6 min, *t_R* (2*R*,3*S*) 47.8 min, 91:9 er; **IR** *v*_{max} (film) 1780 (C=O, ester), 1526, 1487, 1179, 1103, 957; **¹H NMR** (400 MHz, CDCl₃) δ_H : 2.75 (3H, s, CH₃), 3.90 (1H, d, *J* 3.9, C(4)*H*), 4.18 (1H, dd, *J* 12.2, 3.9, C(3)*H*), 5.07 (1H, d, *J* 12.2, C(2)*H*), 6.92 (1H, tt, *J* 9.8, 7.0, Ar¹C(4)*H*), 7.38 – 7.42 (3H, m, Ar²C(3,4,5)*H*), 7.48 – 7.62 (4H, m, Ar²C(6)*H* and Ar³C(3,4,5)*H*), 7.66 – 7.70 (2H, m, Ar³C(2,6)*H*); **¹⁹F{¹H} NMR** (376 MHz, CDCl₃) δ_F : -152.9 – -152.8 (m), -138.8 – -138.6 (m); **¹³C{¹H} NMR** (126 MHz, CDCl₃) δ_C : 19.9 (CH₃), 27.3 (C(4)*H*), 48.0 (C(2)*H*), 48.6 (C(3)*H*), 103.5 (t, *J* 22.8, Ar¹C(4)*H*), 111.2 (CN), 111.4 (CN), 126.0 (Ar²C(6)*H*), 127.9 (Ar²C(5)*H*), 128.4 (Ar³C(2,6)*H*), 128.6 – 129.1 (m, Ar¹C(1)), 129.5 (Ar³C(3,5)*H*), 129.7 (Ar³C(4)*H*), 129.9 (Ar²C(4)*H*), 130.8 (Ar²C(1)), 132.3 (Ar²C(3)*H*), 133.7 (Ar³C(1)), 138.2 (Ar²C(2)), 139.0 – 141.4 (m, Ar¹CF), 144.6 – 146.9 (m, Ar¹CF), 166.8 (C(1)); **HRMS** (*EL*⁺) C₂₅H₁₆O₂N₂F₄ [*M*]⁺ found 452.1134, requires 452.1142 (-1.8 ppm).

Syn-**S19** (20 mg, 9%) as a colourless glass. $[\alpha]_D^{20}$ -102.0 (*c* 0.5 in CHCl₃); **Chiral HPLC analysis**, Chiralcel OD-H (93:7 *n*-hexane : IPA, flow rate 1.5 mLmin⁻¹, 211 nm, 30 °C) *t_R* (2*S*,3*S*) 7.3 min, *t_R* (2*R*,3*R*) 11.4 min, 83:17 er; **IR** *v*_{max} (film) 2922 (C-H), 1771 (C=O, ester), 1526, 1487, 1456, 1273, 1180, 1132, 1103, 959; **¹H NMR** (400 MHz, CDCl₃) δ_H : 2.34 (3H, s, CH₃), 4.09 (1H, dd, *J* 11.6, 5.0, C(3)*H*), 4.79 (1H, d, *J* 5.0, C(4)*H*), 4.93 (1H, d, *J* 11.6, C(2)*H*), 6.99 – 7.09 (2H, m, Ar²C(3)*H* and Ar¹C(4)*H*), 7.10 – 7.19 (2H, m, Ar²C(4,5)*H*), 7.24 – 7.33 (6H, m, Ar²C(6)*H* and Ar³C(2,3,4,5,6)*H*); **¹⁹F{¹H} NMR** (376 MHz, CDCl₃) δ_F : -152.6 – 152.5 (m), -138.3 – -138.2 (m); **¹³C{¹H} NMR** (126 MHz, CDCl₃) δ_C : 19.8 (CH₃), 27.7 (C(4)*H*), 47.8 (C(3)*H*), 48.0 (C(2)*H*), 103.9 (t, *J* 22.7, Ar¹C(4)*H*), 111.1 (CN), 111.3 (CN), 126.8 (Ar²C(5,6)*H*), 128.3 (Ar³C(2,6)*H*), 128.6 (Ar²C(4)*H*), 128.7 – 129.0 (m, Ar¹C(1)), 129.0 (Ar³C(3,5)*H*), 129.3 (Ar³C(4)*H*), 131.2 (Ar²C(3)*H*), 131.8 (Ar²C(1)), 133.3 (Ar³C(1)), 136.7 (Ar²C(2)), 139.1 – 141.5 (m, Ar¹CF), 144.8 – 147.1 (m, Ar¹CF), 169.2 (C(1)); **HRMS** (*EL*⁺) C₂₅H₁₆O₂N₂F₄ [*M*]⁺ found 452.1142, requires 452.1142 (±0.0 ppm).

(2*R*,3*S*)-2,3,5,6-tetrafluorophenyl 4,4-dicyano-3-phenyl-2-(thiophen-3-yl)butanoate (**24**) and (2*R*,3*R*)-2,3,5,6-tetrafluorophenyl 4,4-dicyano-3-phenyl-2-(thiophen-3-yl)butanoate (**S20**)




Following General Procedure E, 2,3,5,6-tetrafluorophenyl 2-(thiophen-3-yl)acetate **S13** (218 mg, 0.75 mmol, 1.5 eq), 2-benzylidene malononitrile **2** (78 mg, 0.50 mmol, 1.0 eq), and (4*bR*,11*aS*)-fused-BTM **19** (6.6 mg, 0.025 mmol, 5 mol%) in CPME (1.0 M) gave crude product that was purified by flash silica column chromatography (hexane:acetone 90:10 to 85:15, R_F 0.11 at 90:10) to give a mixture of diastereoisomers (86:14 dr). The diastereoisomers were then separated by flash silica column chromatography (hexane:Et₂O 80:20 to 70:30) to give:

Anti-24 (149 mg, 67%) as a colourless solid. **mp** 93–95 °C; $[\alpha]_D^{20}$ -54.4 (*c* 1.0 in CHCl₃); **Chiral HPLC analysis**, Chiralcel OD-H (97:3 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) t_R (2*R*,3*S*) 27.6 min, t_R (2*S*,3*R*) 31.2 min, 97:3 er; **IR** ν_{max} (film) 2918 (C-H), 2156, 1973, 1782 (C=O, ester), 1526, 1487, 1180, 1115, 959; **¹H NMR** (400 MHz, CDCl₃) δ_H : 3.81 (1H, d, *J* 4.0, C(4)*H*), 3.99 (1H, dd, *J* 12.2, 4.0, C(3)*H*), 4.92 (1H, d, *J* 12.2, C(2)*H*), 6.94 (1H, tt, *J* 9.9, 7.0, Ar¹C(4)*H*), 7.35 (1H, dd, *J* 5.1, 1.4, Ar²C(4)*H*), 7.48 – 7.59 (4H, m, Ar²C(5)*H* and Ar³C(3,4,5)*H*), 7.60 – 7.64 (2H, m, Ar³C(2,6)*H*), 7.66 (1H, dd, *J* 3.0, 1.4, Ar²C(2)*H*); **¹⁹F{¹H} NMR** (376 MHz, CDCl₃) δ_F : -152.7 – 152.6 (m), -138.6 – -138.5 (m); **¹³C{¹H} NMR** (126 MHz, CDCl₃) δ_C : 28.0 (C(4)*H*), 48.8 (C(2)*H*), 48.9 (C(3)*H*), 103.7 (t, *J* 22.7, Ar¹C(4)*H*), 110.7 (CN), 111.2 (CN), 125.9 (Ar²C(2)*H*), 126.0 (Ar²C(4)*H*), 128.2 (Ar³C(2,6)*H*), 128.5 – 129.0 (m, Ar¹C(1)), 129.0 (Ar²C(5)*H*), 129.6 (Ar³C(3,5)*H*), 130.0 (Ar³C(4)*H*), 132.6 (Ar²C(3)), 133.5 (Ar³C(1)), 139.0 – 141.4 (m, Ar¹CF), 144.6 – 147.0 (m, Ar¹CF), 166.2 (C(1)); **HRMS** (*ESI*⁺) C₂₂H₁₃O₂N₂F₄S [*M* + *H*]⁺ found 445.0612, requires 445.0628 (-3.6 ppm).

Syn-S20 (20 mg, 9%) as a colourless glass. $[\alpha]_D^{20}$ -85.0 (c 0.8 in CHCl₃); **Chiral HPLC analysis**, Chiralpak IB (98:2 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t_R* (2*S*,3*S*) 22.6 min, *t_R* (2*R*,3*R*) 29.1 min, 87:13 er; **IR** $\nu_{\max}$ (film) 2920 (C-H), 1773 (C=O, ester), 1526, 1487, 1456, 1179, 1128, 1090, 957; **¹H NMR** (500 MHz, CDCl₃) δ_H : 4.00 (1H, dd, *J* 10.8, 5.6, C(3)*H*), 4.58 (1H, d, *J* 5.6, C(4)*H*), 4.85 (1H, d, *J* 10.8, C(2)*H*), 6.87 (1H, dd, *J* 5.1, 1.3, Ar²C(4)*H*), 7.07 (1H, tt, *J* 9.8, 7.1, Ar¹C(4)*H*), 7.12 (1H, dd, *J* 3.0, 1.3, Ar²C(2)*H*), 7.24 (1H, dd, *J* 5.1, 3.0, Ar²C(5)*H*), 7.27 – 7.32 (2H, m, Ar³C(2,6)*H*), 7.33 – 7.39 (3H, m, Ar³C(3,4,5)*H*); **¹⁹F{¹H} NMR** (376 MHz, CDCl₃) δ_F : -152.5 – 152.4 (m), -138.1 – -137.9 (m); **¹³C{¹H} NMR** (126 MHz, CDCl₃) δ_C : 27.7 (C(4)*H*), 48.0 (C(3)*H*), 48.2 (C(2)*H*), 104.0 (t, *J* 22.7, Ar¹C(4)*H*), 110.9 (CN), 111.1 (CN), 125.0 (Ar²C(2)*H*), 126.5 (Ar²C(4)*H*), 127.0 (Ar²C(5)*H*), 128.5 (Ar³C(2,6)*H*), 128.7 – 129.1 (m, Ar¹C(1)), 129.2 (Ar³C(3,5)*H*), 129.5 (Ar³C(4)*H*), 132.3 (Ar²C(3)), 133.1 (Ar³C(1)), 139.2 – 141.5 (m, Ar¹CF), 144.8 – 147.2 (m, Ar¹CF), 168.2 (C(1)); **HRMS** (*ESI*⁺) C₂₂H₁₃O₂N₂F₄S [*M* + *H*]⁺ found 445.0629, requires 445.0628 (+0.2 ppm).

2,3,5,6-tetrafluorophenyl (*S,E*)-2-((*S*)-2,2-dicyano-1-phenylethyl)pent-3-enoate (25) and 2,3,5,6-tetrafluorophenyl (*S,E*)-2-((*R*)-2,2-dicyano-1-phenylethyl)pent-3-enoate (S21)




Following General Procedure E, 2,3,5,6-tetrafluorophenyl (*E*)-pent-3-enoate **S14** (186 mg, 0.75 mmol, 1.5 eq), 2-benzylidenemalononitrile **2** (78 mg, 0.50 mmol, 1.0 eq), and (4*bR*,11*aS*)-fused-BTM **19** (6.6 mg, 0.025 mmol, 5 mol%) in CPME (1.0 M) gave crude product (77:23 dr) that was purified by flash silica column chromatography (hexane:Et₂O 90:10 to 80:20) to give:

Anti-**25** (83 mg, 41%) as a colourless solid. **mp** 84–86 °C; $[\alpha]_D^{20}$ -95.2 (c 1.0 in CHCl₃); **Chiral HPLC analysis**, Chiralcel OD-H (95:5 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t_R* (2*S*,3*S*) 12.3 min, *t_R* (2*R*,3*R*) 19.9 min, 99:1 er; **IR** $\nu_{\max}$ (film) 2920 (C-H), 1780 (C=O, ester), 1526, 1487, 1179, 1111, 1065, 959; **¹H NMR** (400 MHz, CDCl₃) δ_H : 1.92 (3H, dd, *J* 6.6, 1.7, CH₃), 3.69 (1H, dd, *J* 11.8, 4.0, C(3)*H*), 4.16 (1H, dd, *J* 11.8, 9.6, C(2)*H*), 4.26 (1H, d, *J* 4.0,

C(4)H), 5.62 (1H, ddq, J 14.9, 9.6, 1.7, CH=CHCH₃), 6.23 – 6.35 (1H, m, CH=CHCH₃), 6.96 (1H, tt, J 9.9, 7.0, Ar¹C(4)H), 7.43 – 7.54 (5H, m, Ar²C(2,3,4,5,6)H); ¹⁹F{¹H} NMR (376 MHz, CDCl₃) δ_F : -152.9 – 152.8 (m), -138.8 – -138.6 (m); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ_C : 18.3 (CH₃), 27.9 (C(4)H), 47.2 (C(3)H), 52.0 (C(2)H), 103.6 (t, J 22.7, Ar¹C(4)H), 110.8 (CN), 111.4 (CN), 123.2 (CH=CHCH₃), 128.2 (Ar²C(2,6)H), 128.7 – 129.0 (m, Ar¹C(1)), 129.5 (Ar²C(3,5)H), 129.8 (Ar²C(4)H), 133.5 (Ar²C(1)), 136.9 (CH=CHCH₃), 139.0 – 141.4 (m, Ar¹CF), 144.6 – 147.0 (m, Ar¹CF), 166.6 (C(1)); HRMS (ESI^+) C₂₁H₁₄O₂N₂F₄Na [$M + Na$]⁺ found 425.0900, requires 425.0884 (+3.8 ppm).

Syn-S21 (23 mg, 11%) as a colourless glass. $[\alpha]_D^{20}$ -88.0 (c 0.3 in CHCl₃); **Chiral HPLC analysis**, Chiralcel OD-H (99:1 *n*-hexane : IPA, flow rate 1.5 mLmin⁻¹, 211 nm, 40 °C) t_R (2*R*,3*S*) 16.4 min, t_R (2*S*,3*R*) 23.3 min, 97:3 er; **IR** ν_{max} (film) 2920 (C-H), 1773 (C=O, ester), 1526, 1487, 1179, 1109, 957; ¹H NMR (400 MHz, CDCl₃) δ_H : 1.70 (3H, dd, J 6.5, 1.7, CH₃), 3.82 (1H, dd, J 8.9, 7.1, C(3)H), 4.12 (1H, dd, J 8.9, 8.9, C(2)H), 4.33 (1H, d, J 7.1, C(4)H), 5.36 (1H, ddq, J 15.3, 8.9, 1.7, CH=CHCH₃), 5.82 – 5.94 (1H, m, CH=CHCH₃), 7.07 (1H, tt, J 9.8, 7.1, Ar¹C(4)H), 7.32 – 7.39 (2H, m, Ar²C(2,6)H), 7.41 – 7.51 (3H, m, Ar²C(3,4,5)H); ¹⁹F{¹H} NMR (376 MHz, CDCl₃) δ_F : -152.6 – 152.4 (m), -138.2 – -138.1 (m); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ_C : 18.1 (CH₃), 27.5 (C(4)H), 47.4 (C(3)H), 50.1 (C(2)H), 103.9 (t, J 22.7, Ar¹C(4)H), 110.9 (CN), 111.3 (CN), 122.0 (CH=CHCH₃), 128.7 (Ar²C(2,6)H), 128.9 – 129.2 (m, Ar¹C(1)), 129.3 (Ar²C(3,5)H), 129.6 (Ar²C(4)H), 132.8 (Ar²C(1)), 134.7 (CH=CHCH₃), 139.2 – 141.6 (m, Ar¹CF), 144.8 – 147.2 (m, Ar¹CF), 168.1 (C(1)); HRMS (ESI^+) C₂₁H₁₄O₂N₂F₄Na [$M + Na$]⁺ found 425.0881, requires 425.0884 (-0.7 ppm).

(2*R*,3*S*)-2,3,5,6-tetrafluorophenyl 4,4-dicyano-3-(4-(trifluoromethyl)phenyl)-2-(*p*-tolyl)butanoate (**26**) and (2*R*,3*R*)- 2,3,5,6-tetrafluorophenyl 4,4-dicyano-3-(4-(trifluoromethyl)phenyl)-2-(*p*-tolyl)butanoate (**S22**)




Following General Procedure E, 2,3,5,6-tetrafluorophenyl 2-(*p*-tolyl)acetate **9** (224 mg, 0.75 mmol, 1.5 eq), 2-(4-(trifluoromethyl)benzylidene)malononitrile **S9** (111 mg, 0.50 mmol, 1.0 eq), and (4*bR*,11*aS*)-fused-BTM **19** (6.6 mg, 0.025 mmol, 5 mol%) in CPME (1.0 M) gave crude product (85:15 dr) that was purified by flash silica chromatography (hexane:acetone 90:10, R_F 0.21) to give a mixture of diastereoisomers (85:15 dr). The diastereoisomers were then separated by flash silica column chromatography (hexane:EtOAc 95:5 to 90:10) to give:

Anti-26 (162 mg, 62%) as a colourless solid. **mp** 139–141 °C; $[\alpha]_D^{20}$ -52.8 (c 1.3 in CHCl_3); **Chiral HPLC analysis**, Chiralcel OD-H (93:7 *n*-hexane : IPA, flow rate 2.0 mLmin⁻¹, 211 nm, 30 °C) t_R (2*S*,3*R*) 7.0 min, t_R (2*R*,3*S*) 12.6 min, 98:2 er; **IR** ν_{max} (film) 1780 (C=O, ester), 1528, 1487, 1327, 1171, 1113, 1070, 957; **¹H NMR** (400 MHz, CDCl_3) δ_H : 2.46 (3H, s, CH_3), 3.77 (1H, d, J 4.0, C(4)*H*), 4.05 (1H, dd, J 12.2, 4.0, C(3)*H*), 4.69 (1H, d, J 12.2, C(2)*H*), 6.94 (1H, tt, J 9.8, 7.0, Ar¹C(4)*H*), 7.35 – 7.41 (2H, m, Ar²C(3,5)*H*), 7.49 – 7.54 (2H, m, Ar²C(2,6)*H*), 7.75 – 7.84 (4H, m, Ar³C(2,3,5,6)*H*); **¹⁹F{¹H} NMR** (376 MHz, CDCl_3) δ_F : -153.1 – 152.9 (m), -138.5 – -138.3 (m), -62.9 (s); **¹³C NMR** (126 MHz, CDCl_3) δ_C : 21.2 (CH_3), 27.5 (C(4)*H*), 48.7 (C(3)*H*), 52.7 (C(2)*H*), 103.7 (t, J 22.7, Ar¹C(4)*H*), 110.3 (CN), 111.0 (CN), 123.7 (q, J 272.4, CF_3), 126.5 (q, J 3.7, Ar³C(3,5)), 128.0 (Ar²C(2,6)), 128.5 – 128.8 (m, Ar¹C(1)), 128.9 (Ar³C(2,6)), 129.0 (Ar²C(1)), 131.1 (Ar²C(3,5)), 132.1 (q, J 32.9 Ar³C(4)), 137.8 (Ar³C(1)), 139.0 – 141.3 (m, Ar¹CF), 140.6 (Ar²C(4)), 144.6 – 147.0 (m, Ar¹CF), 166.5 (C(1)); **HRMS** (ESI^-) $\text{C}_{26}\text{H}_{14}\text{O}_2\text{N}_2\text{F}_7$ [$M - H$]⁻ found 519.0956, requires 519.0949 (+1.4 ppm).

Syn-S22 (19 mg, 7%) as a colourless glass. $[\alpha]_D^{20}$ -95.3 (*c* 0.9 in CHCl₃); **Chiral HPLC analysis**, Chiralcel OD-H (95:5 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*S*,3*S*) 10.7 min, *t*_R (2*R*,3*R*) 24.6 min, 87:13 er; **IR** *v*_{max} (film) 2924 (C-H), 1771 (C=O, ester), 1528, 1487, 1325, 1179, 1130, 1115, 1070, 959; **¹H NMR** (400 MHz, CDCl₃) δ _H: 2.28 (3H, s, CH₃), 4.09 (1H, dd, *J* 11.4, 5.1, C(3)*H*), 4.62 (1H, d, *J* 11.4, C(2)*H*), 4.69 (1H, d, *J* 5.1, C(4)*H*), 7.01 – 7.12 (5H, m, Ar²C(2,3,5,6)*H* and Ar¹C(4)*H*), 7.40 – 7.47 (2H, m, Ar³C(2,6)*H*), 7.57 – 7.63 (2H, m, Ar³C(3,5)*H*); **¹⁹F{¹H} NMR** (376 MHz, CDCl₃) δ _F: -152.6 – 152.4 (m), -138.1 – -138.0 (m), -62.9 (s); **¹³C NMR** (126 MHz, CDCl₃) δ _C: 21.1 (CH₃), 27.6 (C(4)*H*), 47.7 (C(3)*H*), 52.0 (C(2)*H*), 104.0 (t, *J* 22.7, Ar¹C(4)*H*), 110.7 (CN), 110.8 (CN), 123.6 (q, *J* 272.5, CF₃), 126.1 (q, *J* 3.7, Ar³C(3,5)), 128.1 (Ar²C(2,6)), 129.1 – 129.4 (m, Ar³C(2,6), Ar²C(1), and Ar¹C(1)), 130.1 (Ar²C(3,5)), 131.5 (q, *J* 32.8 Ar³C(4)), 137.1 (Ar³C(1)), 139.1 (Ar²C(4)), 139.2 – 141.4 (m, Ar¹CF), 144.8 – 147.1 (m, Ar¹CF), 168.7 (C(1)); **HRMS** (*ESI*⁺) C₂₆H₁₅O₂N₂F₇Na [*M* + Na]⁺ found 543.0908, requires 543.0914 (-1.1 ppm).

(2*R*,3*S*)-2,3,5,6-tetrafluorophenyl 4,4-dicyano-3-(4-nitrophenyl)-2-(*p*-tolyl)butanoate (27) and (2*R*,3*R*)-2,3,5,6-tetrafluorophenyl 4,4-dicyano-3-(4-nitrophenyl)-2-(*p*-tolyl)butanoate (S23)




Following General Procedure E, 2,3,5,6-tetrafluorophenyl 2-(*p*-tolyl)acetate **9** (224 mg, 0.75 mmol, 1.5 eq), 2-(4-nitrobenzylidene)malononitrile **S7** (100 mg, 0.50 mmol, 1.0 eq), and (4*bR*,11*aS*)-fused-BTM **19** (6.6 mg, 0.025 mmol, 5 mol%) in CH₂Cl₂ (1.0 M) gave crude product (68:32 dr) that was purified by flash silica chromatography (hexane:EtOAc 95:5 to 80:20) to give:

Anti-27 (147 mg, 59%) as a colourless solid. **mp** 73–75 °C; $[\alpha]_D^{20}$ -42.7 (*c* 1.5 in CHCl₃); **Chiral HPLC analysis**, Chiralcel OD-H (93:7 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 40 °C) *t*_R (2*S*,3*R*) 25.3 min, *t*_R (2*R*,3*S*) 46.2 min, 99:1 er; **IR** *v*_{max} (film) 2903 (C-H), 1780 (C=O, ester), 1526, 1487, 1350, 1179, 1113, 957; **¹H NMR** (400 MHz, CDCl₃) δ _H: 2.46 (3H, s, CH₃),

3.79 (1H, d, J 4.0, C(4) H), 4.10 (1H, dd, J 12.2, 4.0, C(3) H), 4.68 (1H, d, J 12.2, C(2) H), 6.95 (1H, tt, J 9.8, 7.0, Ar¹C(4) H), 7.35 – 7.41 (2H, m, Ar²C(3,5) H), 7.46 – 7.54 (2H, m, Ar²C(2,6) H), 7.81 – 7.88 (2H, m, Ar³C(2,6) H), 8.37 – 8.44 (2H, m, Ar³C(3,5) H); ¹⁹F{¹H} NMR (376 MHz, CDCl₃) δ_F : -153.1 – 152.9 (m), -138.2 – -138.1 (m); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ_C : 21.3 (CH₃), 27.3 (C(4)), 48.6 (C(3)), 52.6 (C(2)), 103.9 (t, J 22.7, Ar¹C(4)), 110.2 (CN), 110.8 (CN), 124.6 (Ar³C(3,5)), 128.1 (Ar²C(2,6)), 128.6 – 128.8 (m, Ar²C(1) and Ar¹C(1)), 129.6 (Ar³C(2,6)), 131.2 (Ar²C(3,5)), 138.9 – 141.4 (m, Ar¹CF), 140.8 (Ar²C(4)), 140.8 (Ar³C(1)), 144.5 – 147.2 (m, Ar¹CF), 148.8 (Ar³C(4)), 166.5 (C(1)). HRMS (ESI^+) C₂₅H₁₅O₄N₃F₄²³Na [$M + Na$]⁺ found 520.0894, requires 520.0891 (+0.6 ppm).


Syn-S23 (54 mg, 22%) as a colourless glass. $[\alpha]_D^{20}$ -160.4 (c 1.4 in CHCl₃); **Chiral HPLC analysis**, Chiralcel OD-H (93:7 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 40 °C) t_R (2*S*,3*S*) 16.9 min, t_R (2*R*,3*R*) 34.7 min, 99:1 er; **IR** ν_{max} (film) 2926 (C-H), 1771 (C=O, ester), 1526, 1487, 1350, 1180, 1134, 1115, 959; ¹H NMR (400 MHz, CDCl₃) δ_H : 2.28 (3H, s, CH₃), 4.17 (1H, dd, J 11.4, 5.2, C(3) H), 4.63 (1H, d, J 11.4, C(2) H), 4.73 (1H, d, J 5.2, C(4) H), 7.02 – 7.11 (5H, m, Ar¹C(4) H and Ar²C(2,3,5,6) H), 7.48 – 7.53 (2H, m, Ar³C(2,6) H), 8.17 – 8.22 (2H, m, Ar³C(3,5) H); ¹⁹F{¹H} NMR (376 MHz, CDCl₃) δ_F : -152.6 – 152.4 (m), -138.0 – -137.9 (m); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ_C : 21.1 (CH₃), 27.4 (C(4)), 47.6 (C(3)), 51.9 (C(2)), 104.1 (t, J 22.7, Ar¹C(4)), 110.5 (CN), 110.7 (CN), 124.3 (Ar³C(3,5)), 128.1 (Ar²C(2,6)), 128.7 – 129.0 (m, Ar¹C(1)), 129.1 (Ar²C(1)), 129.9 (Ar³C(2,6)), 130.2 (Ar²C(3,5)), 139.0 – 141.4 (m, Ar¹CF), 139.4 (Ar²C(4)), 140.2 (Ar³C(1)), 144.8 – 147.2 (m, Ar¹CF), 148.3 (Ar³C(4)), 168.5 (C(1)). HRMS (ESI^+) C₂₅H₁₅O₄N₃F₄²³Na [$M + Na$]⁺ found 520.0890, requires 520.0891 (-0.2 ppm).

(2*R*,3*S*)-2,3,5,6-tetrafluorophenyl 4,4-dicyano-3-(4-fluorophenyl)-2-(*p*-tolyl)butanoate
(28)



Following General Procedure E, 2,3,5,6-tetrafluorophenyl 2-(*p*-tolyl)acetate **9** (224 mg, 0.75 mmol, 1.5 eq), 2-(4-fluorobenzylidene)malononitrile **S5** (86 mg, 0.50 mmol, 1.0 eq), and (4*bR*,11*aS*)-fused-BTM **19** (6.6 mg, 0.025 mmol, 5 mol%) in CPME (1.0 M) gave crude product (95:5 dr) that was purified by flash silica chromatography (hexane:acetone 90:10, R_F 0.31 at 80:20) to give a mixture of diastereoisomers (95:5 dr). The mixture of diastereoisomers was then subjected to flash silica column chromatography (hexane:Et₂O 90:10 to 80:20, R_F 0.18 at 80:20) to afford the title compound (152 mg, 65%, single major diastereoisomer) as a colourless solid. **mp** 165–167 °C; $[\alpha]_D^{20}$ -64.0 (*c* 1.0 in CHCl₃); **Chiral HPLC analysis**, Chiralcel OD-H (95:5 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) t_R (2*S*,3*R*) 16.4 min, t_R (2*R*,3*S*) 23.4 min, 99:1 er; **IR** ν_{max} (film) 1780 (C=O, ester), 1526, 1514, 1487, 1105, 959; **¹H NMR** (500 MHz, CDCl₃) δ_H : 2.45 (3H, s, CH₃), 3.72 (1H, d, *J* 3.9, C(4)*H*), 3.98 (1H, dd, *J* 12.2, 3.9, C(3)*H*), 4.62 (1H, d, *J* 12.2, C(2)*H*), 6.94 (1H, tt, *J* 9.8, 7.0, Ar¹C(4)*H*), 7.19 – 7.26 (2H, m, Ar³C(3,5)*H*), 7.33 – 7.39 (2H, m, Ar²C(3,5)*H*), 7.48 – 7.53 (2H, m, Ar²C(2,6)*H*), 7.59 – 7.66 (2H, m, Ar³C(2,6)*H*); **¹⁹F{¹H} NMR** (470 MHz, CDCl₃) δ_F : -152.9 – -152.8 (m), -138.6 – -138.5 (m), -111.0 (s); **¹³C NMR** (126 MHz, CDCl₃) δ_C : 21.3 (CH₃), 27.8 (C(4)*H*), 48.3 (C(3)*H*), 53.0 (C(2)*H*), 103.7 (t, *J* 22.7, Ar¹C(4)*H*), 110.5 (CN), 111.2 (CN), 116.7 (d, *J* 21.9, Ar³C(3,5)*H*), 128.0 (Ar²C(2,6)*H*), 128.6 – 129.0 (m, Ar¹C(1)), 129.3 (Ar²C(1)), 129.6 (d, *J* 3.3, Ar³C(1)), 130.2 (d, *J* 8.4, Ar³C(2,6)*H*), 131.0 (Ar²C(3,5)*H*), 139.0 – 141.3 (m, Ar¹CF), 140.4 (Ar²C(4)), 144.6 – 147.0 (m, Ar¹CF), 163.5 (d, *J* 249.7, Ar³C(4)), 166.6 (C(1)); **HRMS** (EI^+) C₂₅H₁₅O₂N₂F₅ [*M*]⁺ found 470.1058, requires 470.1048 (+2.1 ppm).

(2*R*,3*S*)-2,3,5,6-tetrafluorophenyl 4,4-dicyano-3-(4-chlorophenyl)-2-(*p*-tolyl)butanoate (29) and (2*R*,3*R*)- 2,3,5,6-tetrafluorophenyl 4,4-dicyano-3-(4-chlorophenyl)-2-(*p*-tolyl)butanoate (S24)



Following General Procedure E, 2,3,5,6-tetrafluorophenyl 2-(*p*-tolyl)acetate **9** (224 mg, 0.75 mmol, 1.5 eq), 2-(4-chlorobenzylidene)malononitrile **S8** (94 mg, 0.50 mmol, 1.0 eq), and (4*bR*,11*aS*)-fused-BTM **19** (6.6 mg, 0.025 mmol, 5 mol%) in CPME (0.5 M) gave crude product (80:20 dr) that was purified by flash silica chromatography (hexane:acetone 90:10, R_F 0.09) to give a mixture of diastereoisomers (80:20 dr). The diastereoisomers were then separated by flash silica column chromatography (hexane:Et₂O 90:10 to 75:25) to give:

Anti-**29** (125 mg, 51%) as a colourless solid. **mp** 153–155 °C; $[\alpha]_D^{20}$ -44.5 (*c* 1.1 in CHCl₃);


Chiral HPLC analysis, Chiralcel OD-H (95:5 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) t_R (2*S*,3*R*) 16.8 min, t_R (2*R*,3*S*) 27.9 min, 99:1 er; **IR** ν_{max} (film) 1782 (C=O, ester), 1526, 1487, 1113; **¹H NMR** (400 MHz, CDCl₃) δ_H : 2.45 (3H, s, CH₃), 3.72 (1H, d, *J* 3.9, C(4)*H*), 3.96 (1H, dd, *J* 12.2, 3.9, C(3)*H*), 4.62 (1H, d, *J* 12.2, C(2)*H*), 6.95 (1H, tt, *J* 9.8, 7.0, Ar¹C(4)*H*), 7.34 – 7.38 (2H, m, Ar²C(3,5)*H*), 7.47 – 7.54 (4H, m, Ar²C(2,6)*H* and Ar³C(3,5)*H*), 7.55 – 7.60 (2H, m, Ar³C(2,6)*H*); **¹⁹F{¹H} NMR** (376 MHz, CDCl₃) δ_F : -152.8 – 152.7 (m), -138.5 – -138.4 (m); **¹³C{¹H} NMR** (126 MHz, CDCl₃) δ_C : 21.3 (CH₃), 27.7 (C(4)*H*), 48.4 (C(3)*H*), 52.8 (C(2)*H*), 103.7 (t, *J* 22.7, Ar¹C(4)*H*), 110.4 (CN), 111.1 (CN), 128.0 (Ar²C(2,6)*H*), 128.6 – 129.0 (m, Ar¹C(1)), 129.2 (Ar²C(1)), 129.6 (Ar³C(2,6)*H*), 129.8 (Ar³C(3,5)*H*), 131.0 (Ar²C(3,5)*H*), 132.2 (Ar³C(1)), 136.0 (Ar³C(4)), 139.0 – 141.3 (m, Ar¹CF), 140.5 (Ar²C(4)), 144.6 – 147.0 (m, Ar¹CF), 166.6 (C(1)); **HRMS** (MALDI (no matrix)⁺) C₂₅H₁₅³⁵ClO₂N₂F₄Na [*M* + *Na*]⁺ found 509.0635, requires 509.0650 (-2.9 ppm).

Syn-**S24** (28 mg, 12%) as a colourless solid. **mp** 72–74 °C; $[\alpha]_D^{20}$ -155.3 (*c* 0.9 in CHCl₃);

Chiral HPLC analysis, Chiralcel OD-H (93:7 *n*-hexane : IPA, flow rate 1.5 mLmin⁻¹, 211 nm, 30 °C) t_R (2*S*,3*S*) 6.5 min, t_R (2*R*,3*R*) 11.6 min, 96:4 er; **IR** ν_{max} (film) 1769 (C=O, ester),

1526, 1487, 1132, 1111, 1096; ^1H NMR (400 MHz, CDCl_3) δ_{H} : 2.29 (3H, s, CH_3), 4.00 (1H, dd, J 11.3, 5.1, C(3)H), 4.57 (1H, d, J 11.3, C(2)H), 4.64 (1H, d, J 5.1, C(4)H), 7.00 – 7.10 (5H, m, $\text{Ar}^2\text{C}(2,3,5,6)\text{H}$ and $\text{Ar}^1\text{C}(4)\text{H}$), 7.20 – 7.26 (2H, m, $\text{Ar}^3\text{C}(2,6)\text{H}$), 7.27 – 7.33 (2H, m, $\text{Ar}^3\text{C}(3,5)\text{H}$); $^{19}\text{F}\{^1\text{H}\}$ NMR (376 MHz, CDCl_3) δ_{F} : -152.6 – 152.4 (m), -138.2 – -138.1 (m); $^{13}\text{C}\{^1\text{H}\}$ NMR (176 MHz, CDCl_3) δ_{C} : 21.1 (CH_3), 27.7 (C(4)H), 47.4 (C(3)H), 52.1 (C(2)H), 104.0 (t, J 22.7, $\text{Ar}^1\text{C}(4)\text{H}$), 110.8 (CN), 111.0 (CN), 128.2 ($\text{Ar}^2\text{C}(2,6)\text{H}$), 128.8 – 129.1 (m, $\text{Ar}^1\text{C}(1)$), 129.4 ($\text{Ar}^3\text{C}(3,5)\text{H}$), 129.5 ($\text{Ar}^2\text{C}(1)$), 130.0 ($\text{Ar}^2\text{C}(3,5)\text{H}$ and $\text{Ar}^3\text{C}(2,6)\text{H}$), 131.6 ($\text{Ar}^3\text{C}(1)$), 135.4 ($\text{Ar}^3\text{C}(4)$), 139.0 ($\text{Ar}^2\text{C}(4)$), 139.4 – 141.2 (m, Ar^1CF), 145.0 – 146.9 (m, Ar^1CF), 168.8 (C(1)); HRMS (*MALDI (no matrix)* $^+$) $\text{C}_{25}\text{H}_{15}^{35}\text{ClO}_2\text{N}_2\text{F}_4\text{Na}$ [$M + \text{Na}$] $^+$ found 509.0631, requires 509.0650 (-3.7 ppm).

(2*R*,3*S*)-2,3,5,6-tetrafluorophenyl **4,4-dicyano-2-(*p*-tolyl)-3-(3-(trifluoromethyl)phenyl)butanoate (30)** and **(2*R*,3*R*)-2,3,5,6-tetrafluorophenyl 4,4-dicyano-2-(*p*-tolyl)-3-(3-(trifluoromethyl)phenyl)butanoate (S25)**



Following General Procedure E, 2,3,5,6-tetrafluorophenyl 2-(*p*-tolyl)acetate **9** (224 mg, 0.75 mmol, 1.5 eq), 2-(3-(trifluoromethyl)benzylidene)malononitrile **S10** (111 mg, 0.50 mmol, 1.0 eq), and (4*bR*,11*aS*)-fused-BTM **19** (6.6 mg, 0.025 mmol, 5 mol%) in CPME (1.0 M) gave crude product that was purified by flash silica column chromatography (hexane:acetone 90:10, R_{F} 0.10) to give a mixture of diastereoisomers (85:15 dr). The diastereoisomers were then separated by flash silica column chromatography (hexane:Et₂O 90:10 to 75:25) to give:

Anti-**30** (193 mg, 74%) as a colourless solid. mp 46–48 °C; $[\alpha]_{\text{D}}^{20}$ -53.0 (c 1.0 in CHCl_3); **Chiral HPLC analysis**, Chiralcel OD-H (97:3 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) t_{R} (2*S*,3*R*) 25.8 min, t_{R} (2*R*,3*S*) 31.2 min, 97:3 er; **IR** ν_{max} (film) 2924 (C-H), 1780 (C=O, ester), 1526, 1487, 1329, 1169, 1128, 1076, 959; ^1H NMR (400 MHz, CDCl_3) δ_{H} : 2.46 (3H, s,


CH₃), 3.76 (1H, d, *J* 4.0, C(4)H), 4.04 (1H, dd, *J* 12.2, 4.0, C(3)H), 4.68 (1H, d, *J* 12.2, C(2)H), 6.94 (1H, tt, *J* 9.9, 7.0, Ar¹C(4)H), 7.34 – 7.41 (2H, m, Ar²C(3,5)H), 7.48 – 7.55 (2H, m, Ar²C(2,6)H), 7.65 – 7.72 (1H, m, Ar³C(5)H), 7.76 – 7.81 (1H, m, Ar³C(4)H), 7.82 – 7.87 (1H, m, Ar³C(6)H), 7.88 (1H, s, Ar³C(2)H); ¹⁹F{¹H} NMR (376 MHz, CDCl₃) δ_F: -153.1 – -153.0 (m), -138.6 – -138.4 (m), -62.9 (s); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ_C: 21.3 (CH₃), 27.5 (C(4)), 48.7 (C(3)), 52.7 (C(2)), 103.7 (t, *J* 22.8, Ar¹C(4)), 110.3 (CN), 110.9 (CN), 123.6 (q, *J* 272.6, CF₃), 125.3 (q, *J* 3.9, Ar³C(2)H), 126.9 (q, *J* 3.6, Ar³C(4)H), 128.0 (Ar²C(2,6)H), 128.5 – 128.9 (m, Ar¹C(1)), 129.0 (Ar²C(1)), 130.2 (Ar³C(5)H), 131.1 (Ar²C(3,5)H), 131.7 (Ar³C(6)H), 132.0 (q, *J* 32.8, Ar³C(3)), 134.8 (Ar³C(1)), 139.0 – 141.3 (m, Ar¹CF), 140.6 (Ar²C(4)), 144.6 – 147.0 (m, Ar¹CF), 166.5 (C(1)). **HRMS** (*ESI*⁺) C₂₆H₁₅O₂N₂F₇Na [*M* + *Na*]⁺ found 543.0904, requires 543.0914 (-1.8 ppm).

Syn-S25 (31 mg, 12%) as a colourless glass. [α]_D²⁰ -112.0 (*c* 0.8 in CHCl₃); **Chiral HPLC analysis**, Chiralcel OD-H (97:3 *n*-hexane : IPA, flow rate 1.5 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*S*,3*S*) 12.3 min, *t*_R (2*R*,3*R*) 21.0 min, 89:11 er; **IR** ν_{max} (film) 2926 (C-H), 1771 (C=O, ester), 1528, 1487, 1329, 1169, 1130, 1076, 959; **¹H NMR** (500 MHz, CDCl₃) δ_H: 2.27 (3H, s, CH₃), 4.10 (1H, dd, *J* 11.1, 5.3, C(3)H), 4.62 (1H, d, *J* 11.1, C(2)H), 4.68 (1H, d, *J* 5.3, C(4)H), 6.99 – 7.11 (5H, m, Ar¹C(4)H and Ar²C(2,3,5,6)H), 7.44 – 7.50 (2H, m, Ar³C(2,5)H), 7.51 – 7.55 (1H, m, Ar³C(6)H), 7.56 – 7.61 (1H, m, Ar³C(4)H); ¹⁹F{¹H} NMR (376 MHz, CDCl₃) δ_F: -152.5 – -152.4 (m), -138.2 – -138.0 (m), -63.0 (s); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ_C: 21.1 (CH₃), 27.5 (C(4)), 47.8 (C(3)), 52.1 (C(2)), 104.0 (t, *J* 22.7, Ar¹C(4)), 110.7 (CN), 110.9 (CN), 123.5 (q, *J* 272.5, CF₃), 125.8 (q, *J* 4.1, Ar³C(2)H), 126.2 (q, *J* 3.7, Ar³C(4)H), 128.2 (Ar²C(2,6)H), 128.6 – 129.2 (m, Ar¹C(1)), 129.3 (Ar²C(1)), 129.7 (Ar³C(5)H), 130.0 (Ar²C(3,5)H), 131.4 (q, *J* 32.8, Ar³C(3)), 132.0 (Ar³C(6)H), 134.2 (Ar³C(1)), 139.1 (Ar²C(4)), 139.1 – 141.4 (m, Ar¹CF), 144.7 – 147.2 (m, Ar¹CF), 168.6 (C(1)). **HRMS** (*ESI*⁺) C₂₆H₁₅O₂N₂F₇Na [*M* + *Na*]⁺ found 543.0905, requires 543.0914 (-1.7 ppm).

(2*R*,3*S*)-2,3,5,6-tetrafluorophenyl

4,4-dicyano-2-(*p*-tolyl)-3-(2-

(trifluoromethyl)phenyl)butanoate (**31**) and (2*R*,3*R*)-2,3,5,6-tetrafluorophenyl 4,4-dicyano-2-(*p*-tolyl)-3-(2-(trifluoromethyl)phenyl)butanoate (**S26**)




Following General Procedure E, 2,3,5,6-tetrafluorophenyl 2-(*p*-tolyl)acetate **9** (224 mg, 0.75 mmol, 1.5 eq), 2-(2-(trifluoromethyl)benzylidene)malononitrile **S11** (111 mg, 0.50 mmol, 1.0 eq), and (4*bR*,11*aS*)-fused-BTM **19** (6.6 mg, 0.025 mmol, 5 mol%) in CPME (1.0 M) gave crude product that was purified by flash silica column chromatography (hexane:acetone 90:10, R_F 0.10) to give the combined *anti* and *syn* diastereoisomers (47:53 dr) (150 mg, 58%) as an inseparable mixture as a colourless solid. **mp** 44–46 °C; $[\alpha]_D^{20}$ -120.0 (c 1.0 in CHCl_3); **IR** ν_{max} (film) 2318, 1773 (C=O, ester), 1528, 1489, 1312, 1179, 1165, 1113, 1038, 959; **HRMS** (ESI^+) $\text{C}_{26}\text{H}_{15}\text{O}_2\text{N}_2\text{F}_7\text{Na}$ $[M + Na]^+$ found 543.0906, requires 543.0914 (-1.5 ppm).

Data for *anti*-**31**: **Chiral HPLC analysis**, Chiralpak AD-H (99:1 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) t_R (2*S*,3*R*) 16.2 min, t_R (2*R*,3*S*) 18.3 min, 99:1 er; **¹H NMR** (500 MHz, CDCl_3) δ_H : 2.46 (3H, s, CH_3), 3.90 (1H, d, J 3.8, C(4)*H*), 4.51 – 4.59 (1H, m, C(3)*H*), 4.84 (1H, d, J 11.8, C(2)*H*), 6.92 (1H, tt, J 9.8, 7.0, Ar¹C(4)*H*), 7.35 – 7.41 (2H, m, Ar²C(3,5)*H*), 7.58 – 7.65 (3H, m, Ar²C(2,6)*H* and Ar³C(4)*H*), 7.76 – 7.81 (1H, m, Ar³C(5)*H*), 7.84 – 7.89 (1H, m, Ar³C(3)*H*), 8.00 – 8.03 (1H, m, Ar³C(6)*H*); **¹⁹F{¹H} NMR** (470 MHz, CDCl_3) δ_F : -153.2 – -153.1 (m), -138.8 – -138.6 (m), -57.2 (s); **¹³C{¹H} NMR** (126 MHz, CDCl_3) δ_C : 21.3 (CH_3), 27.6 (C(4)), 43.2 (C(3)), 53.5 (C(2)), 103.5 (t, J 22.8, Ar¹C(4)), 110.4 (CN), 110.5 (CN), 124.0 (q, J 274.4, CF_3), 127.3 (Ar³C(6)*H*), 127.8 (q, J 5.8, Ar³C(3)*H*), 128.5 (Ar²C(2,6)*H*), 128.5 – 128.8 (m, Ar¹C(1)), 128.9 (Ar²C(1)), 129.5 – 130.2 (m, Ar³C(2) and Ar³C(4)*H*), 130.9 (Ar²C(3,5)*H*), 133.2 (Ar³C(5)*H*), 133.8 (Ar³C(1)), 139.0 – 141.4 (m, Ar¹CF), 140.7 (Ar²C(4)), 144.6 – 147.1 (m, Ar¹CF), 166.1 (C(1)).

Data for *syn*-**S26**: **Chiral HPLC analysis**, Enantiomeric ratio could not be determined; ^1H NMR (500 MHz, CDCl_3) δ_{H} : 2.26 (3H, s, CH_3), 4.52 – 4.59 (1H, m, $\text{C}(3)\text{H}$), 4.76 (1H, d, J 11.1, $\text{C}(2)\text{H}$), 4.81 (1H, d, J 5.8, $\text{C}(4)\text{H}$), 7.00 – 7.10 (5H, m, $\text{Ar}^1\text{C}(4)\text{H}$ and $\text{Ar}^2\text{C}(2,3,5,6)\text{H}$), 7.44 – 7.50 (1H, m, $\text{Ar}^3\text{C}(4)\text{H}$), 7.58 – 7.65 (1H, m, $\text{Ar}^3\text{C}(3)\text{H}$), 7.67 – 7.74 (1H, m, $\text{Ar}^3\text{C}(5)\text{H}$), 7.96 – 8.00 (1H, m, $\text{Ar}^3\text{C}(6)\text{H}$); $^{19}\text{F}\{^1\text{H}\}$ NMR (470 MHz, CDCl_3) δ_{F} : -152.4 – -152.3 (m), -138.4 – -138.2 (m), -56.6 (s); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ_{C} : 21.1 (CH_3), 27.7 ($\text{C}(4)$), 41.6 ($\text{C}(3)$), 53.1 ($\text{C}(2)$), 104.0 (t, J 22.7, $\text{Ar}^1\text{C}(4)$), 110.4 (CN), 111.3 (CN), 123.5 (q, J 274.5, CF_3), 127.2 (q, J 6.0, $\text{Ar}^3\text{C}(3)\text{H}$), 128.0 ($\text{Ar}^3\text{C}(6)\text{H}$), 128.6 ($\text{Ar}^2\text{C}(2,6)\text{H}$), 128.8 – 129.2 (m, $\text{Ar}^1\text{C}(1)$ and $\text{Ar}^2\text{C}(1)$), 129.3 – 129.7 (m, $\text{Ar}^3\text{C}(2)$, $\text{Ar}^3\text{C}(4)\text{H}$ and $\text{Ar}^2\text{C}(3,5)\text{H}$), 132.7 ($\text{Ar}^3\text{C}(5)\text{H}$), 133.1 ($\text{Ar}^3\text{C}(1)$), 138.9 ($\text{Ar}^2\text{C}(4)$), 139.0 – 141.4 (m, Ar^1CF), 144.6 – 147.1 (m, Ar^1CF), 168.8 ($\text{C}(1)$).

(2*R*,3*S*)-2,3,5,6-tetrafluorophenyl 4,4-dicyano-3-(4-methoxyphenyl)-2-(*p*-tolyl)butanoate (**32**) and (2*R*,3*R*)-2,3,5,6-tetrafluorophenyl 4,4-dicyano-3-(4-methoxyphenyl)-2-(*p*-tolyl)butanoate (**S27**)



Following General Procedure E, 2,3,5,6-tetrafluorophenyl 2-(*p*-tolyl)acetate **9** (224 mg, 0.75 mmol, 1.5 eq), 2-(4-methoxybenzylidene)malononitrile **S6** (92 mg, 0.50 mmol, 1.0 eq), and (4*bR*,11*aS*)-fused-BTM **19** (6.6 mg, 0.025 mmol, 5 mol%) in CH_2Cl_2 (1.0 M) gave crude product (80:20 dr) that was purified by flash silica column chromatography (hexane:Et₂O 90:10 to 80:20, R_{F} 0.13 at 80:20) to yield the combined *anti* and *syn* diastereoisomers (80:20 dr) (80 mg, 33%) as an inseparable mixture as a colourless solid. **mp** 88–90 °C; $[\alpha]_{\text{D}}^{20}$ -53.6 (c 1.1 in CHCl_3); **IR** ν_{max} (film) 1780 (C=O, ester), 1612, 1527, 1516, 1487, 1258, 1180, 1109, 957; **HRMS** (EI^+) $\text{C}_{26}\text{H}_{18}\text{O}_3\text{N}_2\text{F}_4$ $[M]^+$ found 482.1250, requires 482.1248 (+0.4 ppm).

Data for major diastereoisomer *anti*-**32**: **Chiral HPLC analysis**, Chiralcel OD-H (98:2 *n*-hexane : IPA, flow rate 1.5 mLmin⁻¹, 211 nm, 30 °C) t_{R} (2*S*,3*R*) 15.6 min, t_{R} (2*R*,3*S*) 19.0 min, 99:1 er; ^1H NMR (400 MHz, CDCl_3) δ_{H} : 2.44 (3H, s, CH_3), 3.70 (1H, d, J 3.9, $\text{C}(4)\text{H}$), 3.87

(3H, s, OCH₃), 3.94 (1H, dd, *J* 12.3, 3.9, C(3)*H*), 4.63 (1H, d, *J* 12.3, C(2)*H*), 6.93 (1H, tt, *J* 9.9, 7.0, Ar¹C(4)*H*), 7.01 – 7.06 (2H, m, Ar³C(3,5)*H*), 7.32 – 7.38 (2H, m, Ar²C(3,5)*H*), 7.48 – 7.54 (2H, m, Ar²C(2,6)*H*), 7.54 – 7.58 (2H, m, Ar³C(2,6)*H*); ¹⁹F{¹H} NMR (470 MHz, CDCl₃) δ_F: -152.6 – 152.5 (m), -138.8 – -138.7 (m); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ_C: 21.3 (CH₃), 28.1 (C(4)*H*), 48.3 (C(3)*H*), 53.0 (C(2)*H*), 55.4 (OCH₃), 103.5 (t, *J* 22.8, Ar¹C(4)*H*), 110.8 (CN), 111.5 (CN), 114.9 (Ar³C(3,5)*H*), 125.5 (Ar³C(1)), 128.0 (Ar²C(2,6)*H*), 128.7 – 129.1 (m, Ar¹C(1)), 129.5 (Ar³C(2,6)*H*), 129.8 (Ar²C(1)), 130.9 (Ar²C(3,5)*H*), 139.1 – 141.3 (m, Ar¹CF), 140.2 (Ar²C(4)), 144.6 – 147.0 (m, Ar¹CF), 160.6 (Ar³C(4)), 166.7 (C(1));

Data for minor diastereoisomer *syn*-**S27**: **Chiral HPLC analysis**, Chiralcel OD-H (98:2 *n*-hexane : IPA, flow rate 1.5 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*S*,3*S*) 12.2 min, *t*_R (2*R*,3*R*) 25.4 min, 96:4 er; ¹H NMR (400 MHz, CDCl₃) (*selected*) δ_H: 2.28 (3H, s, CH₃), 3.78 (3H, s, OCH₃), 6.80 – 6.86 (2H, m, Ar³C(3,5)*H*), 7.18 – 7.24 (2H, m, Ar³C(2,6)*H*); ¹⁹F{¹H} NMR (470 MHz, CDCl₃) δ_F: -152.5 – 152.4 (m), -138.3 – -138.2 (m); ¹³C{¹H} NMR (126 MHz, CDCl₃) (*selected*) δ_C: 21.1 (CH₃), 28.2 (C(4)*H*), 47.4 (C(3)*H*), 52.3 (C(2)*H*), 55.2 (OCH₃), 111.1 (CN), 111.3 (CN), 114.4 (Ar³C(3,5)*H*), 124.9 (Ar³C(1)), 128.3 (Ar²C(2,6)*H*), 129.6 (Ar³C(2,6)*H*), 130.0 (Ar²C(1)), 138.6 (Ar²C(4)), 160.0 (Ar³C(4)), 169.0 (C(1));

10 Isolation of CIDD products by filtration

A CIDD process was in operation for products **14**, **21**, and **28**. This allowed isolation of the respective products by simple filtration washing with cold Et₂O (4 mL). In each case the white solid precipitate was a single diastereoisomer of the product. The filtrate from each reaction contained a mixture of diastereoisomers which were subsequently purified by flash silica column chromatography.


14: Filtration afforded 65% yield, >95:5 dr, 99:1 er. The filtrate was purified to give a mixture of diastereoisomers (63:37 dr) both with 95:5 er in 12% combined yield.

21: Filtration afforded 19% yield, >95:5 dr, 99:1 er. The filtrate (76:24 dr) was purified to give **21** in 46% yield and 99:1 er.

28: Filtration afforded 57% yield, >95:5 dr, 99:1 er. The filtrate (80:20 dr) was purified to give **28** in 17% yield and 94:6 er.

11 Gram scale reaction

(2*R*,3*S*)-2,3,5,6-tetrafluorophenyl 4,4-dicyano-3-phenyl-2-(*p*-tolyl)butanoate (**14**)




Following General Procedure E, 2,3,5,6-tetrafluorophenyl 2-(*p*-tolyl)acetate **9** (1.34 g, 4.5 mmol, 1.5 eq), 2-benzylidene malononitrile **2** (0.46 g, 3.0 mmol, 1.0 eq), and (4*bR*,11*aS*)-fused-BTM **19** (40 mg, 0.15 mmol, 5 mol%) in CPME (1.0 M) gave crude product that was purified directly by recrystallisation from hexane/CH₂Cl₂ to give the title compound as a colourless solid (1.10 g, 81%).

Chiral HPLC analysis, Chiralcel OD-H (99:1 *n*-hexane : IPA, flow rate 1.5 mLmin⁻¹, 211 nm, 30 °C) *t_R* (2*S*,3*R*) 24.1 min, *t_R* (2*R*,3*S*) 29.2 min, >99:1 er.


12 Product derivatisations

(2*R*,3*S*)-*N*-allyl-4,4-dicyano-3-phenyl-2-(*p*-tolyl)butanamide (37)




To a solution of TeFP ester **14** (181 mg, 0.4 mmol, 1.0 equiv.) in anhydrous EtOAc (0.2 M) was added allyl amine (60 μ L, 0.8 mmol 2.0 equiv.) and the reaction mixture stirred at room temperature for 24 h. The mixture was then diluted with EtOAc (10 mL) and washed with 1 M NaOH (3 $\times$ 10 mL) then brine (10 mL). The organic layer was dried over MgSO_4 , filtered, and concentrated under reduced pressure. The crude product was purified by flash silica column chromatography (hexane:EtOAc 80:20 to 70:30, R_F 0.31 at 70:30) to give the title compound (83 mg, 61%) as a colourless solid. **mp** 148–150 $^{\circ}\text{C}$; $[\alpha]_D^{20}$ -62.1 (c 1.0 in CHCl_3); **Chiral HPLC analysis**, Chiralpak IB (90:10 *n*-hexane : IPA, flow rate 1.0 mLmin $^{-1}$, 211 nm, 30 $^{\circ}\text{C}$) t_R (2*S*,3*R*) 8.8 min, t_R (2*R*,3*S*) 14.0 min, >99:1 er; **IR** ν_{max} (film) 3298 (N-H), 2891 (C-H), 1653 (C=O, amide), 1639, 1558, 1541, 1508, 1456, 1261, 991, 914, 760; **^1H NMR** (400 MHz, CDCl_3) δ_{H} : 2.41 (3H, s, CH_3), 3.41 – 3.53 (1H, m, $\text{NCH}^{\text{A}}\text{H}^{\text{B}}$), 3.62 – 3.73 (1H, m, $\text{NCH}^{\text{A}}\text{H}^{\text{B}}$), 3.76 (1H, d, J 3.6, C(4)*H*), 4.00 – 4.12 (2H, m, C(3)*H* and C(2)*H*), 4.58 – 4.67 (1H, m, $\text{CH}=\text{CH}^{\text{A}}\text{H}^{\text{B}}$), 4.81 – 4.89 (1H, m, $\text{CH}=\text{CH}^{\text{A}}\text{H}^{\text{B}}$), 5.36 – 5.50 (1H, m, $\text{CH}=\text{CH}_2$), 5.87 (1H, t, J 5.9, NH), 7.25 – 7.30 (2H, m, $\text{Ar}^1\text{C}(3,5)\text{H}$), 7.43 – 7.52 (5H, m, $\text{Ar}^1\text{C}(2,6)\text{H}$ and $\text{Ar}^2\text{C}(3,4,5)\text{H}$), 7.57 – 7.63 (2H, m, $\text{Ar}^2\text{C}(2,6)\text{H}$); **$^{13}\text{C}\{^1\text{H}\}$ NMR** (126 MHz, CDCl_3) δ_{C} : 21.2 (CH_3), 27.9 (C(4)*H*), 41.7 (NCH_2), 49.0 (C(3)*H*), 54.8 (C(2)*H*), 111.6 (CN), 111.9 (CN), 115.8 ($\text{CH}=\text{CH}_2$), 128.0 ($\text{Ar}^1\text{C}(2,6)\text{H}$), 128.5 ($\text{Ar}^2\text{C}(2,6)\text{H}$), 129.2 ($\text{Ar}^2\text{C}(3,5)\text{H}$), 129.3 ($\text{Ar}^2\text{C}(4)\text{H}$), 130.5 ($\text{Ar}^1\text{C}(3,5)\text{H}$), 132.3 ($\text{Ar}^1\text{C}(1)$), 133.3 ($\text{CH}=\text{CH}_2$), 135.1 ($\text{Ar}^2\text{C}(1)$), 139.2 ($\text{Ar}^1\text{C}(4)$), 169.5 (C(1)); **HRMS** (ESI^+) $\text{C}_{22}\text{H}_{21}\text{ON}_3\text{Na}$ $[M + \text{Na}]^+$ found 366.1576, requires 366.1577 (-0.3 ppm).

(2*R*,3*S*)-methyl 4,4-dicyano-3-phenyl-2-(*p*-tolyl)butanoate (38)



To a solution of TeFP ester **14** (181 mg, 0.4 mmol, 1.0 equiv.) in anhydrous EtOAc (0.25 M) was added anhydrous MeOH (0.41 mL, 10 mmol, 25.0 equiv.) and DMAP (9.8 mg, 0.08 mmol, 0.2 equiv.) and the reaction mixture stirred at RT for 24 h. The mixture was then diluted with EtOAc (10 mL) and washed with sat. Na₂CO₃ (2 × 10 mL) then brine (10 mL). The organic layer was dried over MgSO₄, filtered, and concentrated under reduced pressure. The crude product was purified by flash silica column chromatography (CH₂Cl₂:hexane 50:50 to 100:0, R_F 0.18 at 50:50) to give the title compound (85 mg, 67%) as a colourless solid. **mp** 130–132 °C; $[\alpha]_D^{20}$ -84.9 (*c* 1.0 in CHCl₃); **Chiral HPLC analysis**, Chiralcel OD-H (99:1 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*R*,3*S*) 19.4 min, *t*_R (2*S*,3*R*) 23.7 min, >99:1 er; **IR** ν_{max} (film) 2953 (C-H), 1736 (C=O, ester), 1514, 1456, 1435, 1341, 1306, 1206, 1165, 760; **¹H NMR** (500 MHz, CDCl₃) δ_H: 2.41 (3H, s, CH₃), 3.47 (3H, s, OCH₃), 3.66 (1H, d, *J* 4.0, C(4)*H*), 3.91 (1H, dd, *J* 12.2, 4.0, C(3)*H*), 4.31 (1H, d, *J* 12.2, C(2)*H*), 7.26 – 7.33 (2H, m, Ar¹C(3,5)*H*), 7.41 – 7.51 (5H, m, Ar¹C(2,6)*H* and Ar²C(3,4,5)*H*), 7.53 – 7.60 (2H, m, Ar²C(2,6)*H*); **¹³C{¹H} NMR** (126 MHz, CDCl₃) δ_C: 21.2 (CH₃), 27.8 (C(4)*H*), 49.1 (C(3)*H*), 52.5 (OCH₃), 53.2 (C(2)*H*), 110.9 (CN), 111.6 (CN), 128.0 (Ar¹C(2,6)*H*), 128.4 (Ar²C(2,6)*H*), 129.3 (Ar²C(3,5)*H*), 129.4 (Ar²C(4)*H*), 130.6 (Ar¹C(3,5)*H*), 131.1 (Ar¹C(1)), 134.5 (Ar²C(1)), 139.5 (Ar¹C(4)), 171.0 (C(1)); **HRMS** (*ESI*⁺) C₂₀H₁₈O₂N₂Na [*M* + *Na*]⁺ found 341.1273, requires 341.1260 (+3.8 ppm).

Methyl (2*R*,3*S*,4*R*)-5-amino-4-cyano-5-oxo-3-phenyl-2-(*p*-tolyl)pentanoate (39) and Methyl (2*R*,3*S*,4*S*)-5-amino-4-cyano-5-oxo-3-phenyl-2-(*p*-tolyl)pentanoate (S28)



Adapting the procedure of Maffioli and co-workers,¹² methyl ester **38** (80 mg, 0.25 mmol, 1.0 equiv.), PdCl₂ (4.4 mg, 25 μmol, 10 mol%), and acetamide (62 mg, 1.05 mmol, 4.2 equiv.) were dissolved in THF/H₂O (1.5 mL, 3:1 v/v) and stirred at room temperature for 2 h until complete by TLC. The mixture was then diluted with CH₂Cl₂ and H₂O, and the organic layer separated. The aqueous phase was then extracted with CH₂Cl₂ (× 3) and the combined organics dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by flash silica column chromatography (CH₂Cl₂:Et₂O 90:10, R_F 0.29) to give the title compound (76 mg, 90%) as an inseparable mixture of diastereoisomers (86:14 dr) as a colourless solid. **mp** 71–73 °C; $[\alpha]_D^{20}$ -125 (c 1.0 in CHCl₃); **IR** ν_{max} (film) 3335 (N-H), 3192 (N-H), 2953 (C-H), 1736 (C=O, ester), 1682 (C=O, amide), 1605, 1512, 1342, 1161, 910, 824; **HRMS** (ESI^+) C₂₀H₂₁O₃N₂ [$M + H$]⁺ found 337.1544, requires 337.1547 (-0.9 ppm).

Data for **39**: **Chiral HPLC analysis**, Chiralpak ID (93:7 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 40 °C) t_R (2*R*,3*S*,4*R*) 23.1 min, t_R (2*S*,3*R*,4*S*) 24.3 min, >99:1 er; **¹H NMR** (400 MHz, CDCl₃) δ_H : 2.39 (3H, s, CH₃), 3.28 (1H, d, *J* 4.0, C(4)*H*), 3.41 (3H, s, OCH₃), 4.18 (1H, dd, *J* 12.5, 4.0, C(3)*H*), 4.28 (1H, d, *J* 12.5, C(2)*H*), 5.75 (1H, br s, NH^AH^B), 5.84 (1H, br s, NH^AH^B), 7.24 – 7.28 (2H, m, Ar¹C(3,5)*H*), 7.31 – 7.42 (3H, m, Ar²C(3,4,5)*H*), 7.43 – 7.53 (4H, m, Ar¹C(2,6)*H* and Ar²C(2,6)*H*); **¹³C{¹H} NMR** (126 MHz, CDCl₃) δ_C : 21.2 (CH₃), 42.3 (C(4)*H*), 47.8 (C(3)*H*), 52.2 (OCH₃), 54.1 (C(2)*H*), 116.8 (CN), 128.2 (Ar¹C(2,6)*H*), 128.4 (Ar²C(4)*H*), 128.5 (Ar²C(2,6)*H*), 128.8 (Ar²C(3,5)*H*), 130.3 (Ar¹C(3,5)*H*), 132.1 (Ar¹C(1)), 136.2 (Ar²C(1)), 138.7 (Ar¹C(4)), 165.6 (C(5)), 171.7 (C(1)).

Data for **S28: Chiral HPLC analysis**, Chiralpak ID (93:7 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 40 °C) *t_R* (2*S*,3*R*,4*R*) 21.6 min, *t_R* (2*R*,3*S*,4*S*) 33.7 min, >99:1 er; **¹H NMR** (400 MHz, CDCl₃) (*selected*) δ_H: 2.36 (3H, s, CH₃), 3.40 (3H, s, OCH₃), 3.46 (1H, d, *J* 2.4, C(4)*H*), 4.11 (1H, dd, *J* 12.3, 2.4, C(3)*H*), 4.66 (1H, d, *J* 12.3, C(2)*H*), 5.56 (1H, br s, NH^AH^B), 5.72 (1H, br s, NH^AH^B), 7.16 – 7.22 (2H, m, Ar¹C(3,5)*H*); **¹³C{¹H} NMR** (126 MHz, CDCl₃) δ_C: 21.2 (CH₃), 41.4 (C(4)*H*), 49.1 (C(3)*H*), 52.1 (OCH₃), 52.8 (C(2)*H*), 117.8 (CN), 128.1 (Ar¹C(2,6)*H*), 128.3 (Ar²C(4)*H*), 128.9 (Ar²C(2,6)*H*), 129.4 (Ar²C(3,5)*H*), 129.7 (Ar¹C(3,5)*H*), 132.2 (Ar¹C(1)), 137.7 (Ar²C(1)), 138.5 (Ar¹C(4)), 165.4 (C(5)), 172.3 (C(1)).

13 Single crystal X-ray diffraction data

X-ray diffraction data for all compounds were collected using a Rigaku MM-007HF High Brilliance RA generator/confocal optics [Cu K α radiation (λ = 1.54187 Å)]. Crystals of compounds **5** and **39** were run at 125 K on an XtaLAB P200 diffractometer, while those of compound **14** were run at 173 K on an XtaLAB P100 diffractometer. Intensity data were collected using either ω steps or both ω and φ steps, accumulating area detector images spanning at least a hemisphere of reciprocal space. Data for all compounds analysed were collected using CrystalClear¹³ and processed (including correction for Lorentz, polarisation and absorption) using CrysAlisPro.¹⁴ Structures were solved by either dual-space (SHELXT¹⁵) or direct (SIR2011¹⁶) methods and refined by full-matrix least-squares against F^2 (SHELXL-2018/3¹⁷). Non-hydrogen atoms were refined anisotropically, and carbon-bound hydrogen atoms were refined using a riding model. Hydrogens bound to nitrogen in compound **39** were located from the difference Fourier map and refined isotropically subject to a distance restraint. All calculations were performed using either the CrystalStructure¹⁸ or the Olex2¹⁹ interface. Selected crystallographic data are presented in Tables S7-9.

CCDC 2253984-2253986 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/structures.

Table S7: X-ray data for 5

	(2 <i>R</i> ,3 <i>R</i>)-5
CCDC	2253984
empirical formula	C ₂₅ H ₁₉ N ₃ O ₄
fw	425.44
crystal description	colourless prism
crystal size [mm]	0.20×0.10×0.05
space group	<i>P</i> 2 ₁ 2 ₁ 2 ₁ (#19)
<i>a</i> [Å]	11.65320(10)
<i>b</i> [Å]	13.39570(11)
<i>c</i> [Å]	14.02840(12)
vol [Å ³]	2189.87(3)
<i>Z</i>	4
<i>p</i> (calc) [g/cm ³]	1.290
μ [mm ⁻¹]	0.731
<i>F</i> (000)	888
reflections collected	24536
independent reflections (<i>R</i> _{int})	4447(0.0190)
parameters/restraints	291/0
GOF on <i>F</i> ²	1.029
<i>R</i> ₁ [<i>I</i> > 2σ(<i>I</i>)]	0.0300
<i>wR</i> ₂ (all data)	0.0815
largest diff. peak/hole [e/Å ³]	0.23, -0.26
Flack parameter	0.05(5)






Table S8: X-ray data for 14

	(2R,3S)-14
CCDC	2253985
empirical formula	C ₂₅ H ₁₆ F ₄ N ₂ O ₂
fw	452.41
crystal description	colourless prism
crystal size [mm]	0.18×0.10×0.03
space group	<i>P</i> 2 ₁ 2 ₁ 2 ₁ (#19)
<i>a</i> [Å]	5.87366(8)
<i>b</i> [Å]	9.56529(13)
<i>c</i> [Å]	36.9186(4)
vol [Å] ³	2074.21(5)
<i>Z</i>	4
<i>p</i> (calc) [g/cm ³]	1.449
<i>μ</i> [mm ⁻¹]	1.005
<i>F</i> (000)	928
reflections collected	20708
independent reflections (<i>R</i> _{int})	3758(0.0287)
parameters/restraints	300/0
GOF on <i>F</i> ²	1.230
<i>R</i> ₁ [<i>I</i> > 2σ(<i>I</i>)]	0.0513
<i>wR</i> ₂ (all data)	0.1079
largest diff. peak/hole [e/Å ³]	0.45, -0.54
Flack parameter	0.059(3)









Table S9: X-ray data for 39


(2 <i>R</i> ,3 <i>S</i> ,4 <i>R</i>)-39	
CCDC	2253986
empirical formula	C ₂₀ H ₂₀ N ₂ O ₃
fw	336.38
crystal description	colourless prism
crystal size [mm]	0.21×0.06×0.02
space group	<i>P</i> 2 ₁ 2 ₁ 2 ₁ (#19)
<i>a</i> [Å]	7.83550(10)
<i>b</i> [Å]	9.02620(10)
<i>c</i> [Å]	26.1596(4)
vol [Å] ³	1850.13(4)
<i>Z</i>	4
<i>p</i> (calc) [g/cm ³]	1.208
μ [mm ⁻¹]	0.664
<i>F</i> (000)	712
reflections collected	21639
independent reflections (<i>R</i> _{int})	3772(0.0281)
parameters/restraints	236/2
GOF on <i>F</i> ²	1.049
<i>R</i> ₁ [<i>I</i> > 2σ(<i>I</i>)]	0.0327
<i>wR</i> ₂ (all data)	0.0906
largest diff. peak/hole [e/Å ³]	0.17, -0.16
Flack parameter	-0.03(8)



14 References


1. B. Yan, L. Zuo, X. Chang, T. Liu, M. Cui, Y. Liu, H. Sun, W. Chen and W. Guo, *Org. Lett.*, 2021, **23**, 351-357.
2. J. N. Arokianathar, A. B. Frost, A. M. Z. Slawin, D. Stead and A. D. Smith, *ACS Catal.*, 2018, **8**, 1153-1160.
3. C. McLaughlin, A. M. Z. Slawin and A. D. Smith, *Angew. Chem. Int. Ed.*, 2019, **58**, 15111-15119.
4. R. J. Mayer, M. Breugst, N. Hampel, A. R. Ofial and H. Mayr, *J. Org. Chem.*, 2019, **84**, 8837-8858.
5. M. Trilla, R. Pleixats, M. W. C. Man and C. Bied, *Green Chem.*, 2009, **11**, 1815-1820.
6. A. Karam, N. Villandier, M. Delample, C. K. Koerkamp, J.-P. Douliez, R. Granet, P. Krausz, J. Barrault and F. Jérôme, *Chem. Eur. J.*, 2008, **14**, 10196-10200.
7. Q. Wan, S. Li, Q. Kang, Y. Yuan and Y. Du, *J. Org. Chem.*, 2019, **84**, 15201-15211.
8. G. R. Krishnan and K. Sreekumar, *Eur. J. Org. Chem.*, 2008, **2008**, 4763-4768.
9. M. Zhang, A. Q. Zhang, H. H. Chen, J. Chen and H. Y. Chen, *Synth. Commun.*, 2006, **36**, 3441-3445.
10. S. Balalaie and N. Nemati, *Synth. Commun.*, 2000, **30**, 869-875.
11. A. R. Longstreet, B. S. Campbell, B. F. Gupton and D. T. McQuade, *Org. Lett.*, 2013, **15**, 5298-5301.
12. S. I. Maffioli, E. Marzorati and A. Marazzi, *Org. Lett.*, 2005, **7**, 5237-5239.
13. *CrystalClear-SM Expert v2.1*. Rigaku Americas, The Woodlands, Texas, USA, and Rigaku Corporation, Tokyo, Japan, 2015.
14. *CrysAlisPro v1.171.38.46, v1.171.40.14a, v1.171.41.93a*. Rigaku Oxford Diffraction, Rigaku Corporation, Oxford, U.K., 2015-2020.
15. G. M. Sheldrick, *Acta Crystallogr., Sect. A: Found. Adv.* 2015, **71**, 3-8.
16. M. C. Burla, R. Caliendo, M. Camalli, B. Carrozzini, G. L. Cascarano, C. Giacovazzo, M. Mallamo, A. Mazzone, G. Polidori, and R. Spagna, *J. Appl. Crystallogr.* 2012, **45**, 357-361.
17. G. M. Sheldrick, *Acta Crystallogr., Sect. C: Struct. Chem.* 2015, **71**, 3-8.
18. *CrystalStructure v4.3.0*. Rigaku Americas, The Woodlands, Texas, USA, and Rigaku Corporation, Tokyo, Japan, 2018.
19. O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard, and H. Puschmann, *J. Appl. Crystallogr.* 2009, **42**, 339-341.


Appendix I: ^1H , $^{19}\text{F}\{^1\text{H}\}$, $^{13}\text{C}\{^1\text{H}\}$, 2D ^1H COSY, 2D ^1H – ^{13}C HSQC and 2D ^1H – ^{13}C HMBC NMR Spectra




S1


^1H , MeOD, 400 MHz







S1
 $^{19}\text{F}\{^1\text{H}\}$, MeOD, 377 MHz













$^{19}\text{F}\{^1\text{H}\}$ NMR, CDCl_3 , 470 MHz









anti-S2




syn-S3

2D, ^1H - ^1H COSY, CDCl_3







anti-S2



syn-S3


2D, ^1H - ^{13}C HSQC, CDCl_3






S4


$^{13}\text{C}\{^1\text{H}\}$, CD_2Cl_2 , 126 MHz






S4


2D ^1H - ^1H COSY, CD_2Cl_2










S4

2D ^1H - ^{13}C HSQC, CD_2Cl_2










36




$^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz




1





¹H, CDCl₃, 400 MHz


8

¹H, CDCl₃, 500 MHz

8


 $^{19}\text{F}\{^1\text{H}\}$, CDCl_3 , 376 MHz






S12

^1H , CDCl_3 , 400 MHz




S13

$^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz



S12

$^{19}\text{F}\{^1\text{H}\}$, CDCl_3 , 376 MHz





S12

$^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz

S13


$^{19}\text{F}\{^1\text{H}\}$, CDCl_3 , 376 MHz
 ^1H , CDCl_3 , 400 MHz






33


$^{19}\text{F}\{^1\text{H}\}$, CDCl_3 , 376 MHz







33


$^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz










$^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz







^1H , CDCl_3 , 500 MHz







$^{19}\text{F}\{^1\text{H}\}$, CDCl_3 , 470 MHz







$^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz







¹H, CDCl₃, 500 MHz







$^{19}\text{F}\{^1\text{H}\}$, CDCl_3 , 470 MHz






$^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz









anti-14


$^{19}\text{F}\{^1\text{H}\}$, CDCl_3 , 376 MHz







anti-**14**


$^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz







anti-**14**
2D ^1H - ^1H COSY, CDCl_3







anti-14
2D ^1H - ^{13}C HSQC, CDCl_3






anti-14
2D ^1H - ^{13}C HMBC, CDCl_3






anti-20


^1H , CDCl_3 , 400 MHz






anti-**20**


$^{19}\text{F}\{^1\text{H}\}$, CDCl_3 , 376 MHz







anti-**20**


$^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz







anti-**20**
2D ^1H - ^1H COSY, CDCl_3







anti-20
2D ^1H - ^{13}C HSQC, CDCl_3






anti-**20**
2D ^1H - ^{13}C HMBC, CDCl_3






syn-S17


^1H , CDCl_3 , 400 MHz






***syn*-S17**


$^{19}\text{F}\{^1\text{H}\}$, CDCl_3 , 376 MHz







syn-S17


$^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz








syn-S17
2D ^1H - ^1H COSY, CDCl_3






syn-S17
2D ^1H - ^{13}C HSQC, CDCl_3










***anti*-21**


$^{19}\text{F}\{^1\text{H}\}$, CDCl_3 , 376 MHz







anti-21
 $^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz







anti-**21**
2D ^1H - ^1H COSY, CDCl_3







anti-21
2D ^1H - ^{13}C HSQC, CDCl_3






anti-21
2D ^1H - ^{13}C HMBC, CDCl_3






anti-22


^1H , CDCl_3 , 400 MHz







anti-**22**


$^{19}\text{F}\{^1\text{H}\}$, CDCl_3 , 376 MHz







$^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz









anti-22
2D ^1H - ^1H COSY, CDCl_3






anti-22
2D ^1H - ^{13}C HSQC, CDCl_3










syn-S18


$^{19}\text{F}\{^1\text{H}\}$, CDCl_3 , 376 MHz







syn-S18
 $^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz







syn-S18
2D ^1H - ^1H COSY, CDCl₃







syn-S18
2D ^1H - ^{13}C HSQC, CDCl_3





syn-S18
2D ^1H - ^{13}C HMBC, CDCl_3







anti-**23**

$^{19}\text{F}\{^1\text{H}\}$, CDCl_3 , 376 MHz


-138.638
-138.645
-138.651
-138.673
-138.704
-138.730
-138.739
-152.780
-152.786
-152.791
-152.814
-152.846
-152.867
-152.874







anti-23


$^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz







anti-**23**
2D ^1H - ^1H COSY, CDCl_3






anti-**23**
2D ^1H - ^{13}C HSQC, CDCl_3






syn-S19


$^{19}\text{F}\{^1\text{H}\}$, CDCl_3 , 376 MHz







syn-S19


$^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz







syn-**S19**
2D ^1H - ^1H COSY, CDCl_3






syn-S19
2D ^1H - ^{13}C HSQC, CDCl_3






syn-S19


2D ^1H - ^{13}C HMBC, CDCl_3



anti-24


^1H , CDCl_3 , 400 MHz






anti-**24**


$^{19}\text{F}\{^1\text{H}\}$, CDCl_3 , 376 MHz







anti-**24**


$^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz







anti-24
2D ^1H - ^{13}C HSQC, CDCl_3






anti-**24**
2D ^1H - ^{13}C HMBC, CDCl_3






syn-**S20**


$^{19}\text{F}\{^1\text{H}\}$, CDCl_3 , 376 MHz







syn-S20


$^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz







syn-S20
2D ^1H - ^{13}C HSQC, CDCl_3






syn-S20
2D ^1H - ^{13}C HMBC, CDCl_3






anti-25


¹H, CDCl₃, 400 MHz






anti-**25**


$^{19}\text{F}\{^1\text{H}\}$, CDCl_3 , 376 MHz







anti-**25**


$^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz







anti-**25**
2D ^1H - ^{13}C HSQC, CDCl_3






anti-**25**
2D ^1H - ^{13}C HMBC, CDCl_3






syn-S21


^1H , CDCl_3 , 400 MHz







syn-S21


$^{19}\text{F}\{^1\text{H}\}$, CDCl_3 , 376 MHz







syn-S21
 $^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz






syn-S21
2D ^1H - ^{13}C HSQC, CDCl_3






syn-S21


2D ^1H - ^{13}C HMBC, CDCl_3






anti-**26**


^1H , CDCl_3 , 400 MHz






anti-**26**


$^{19}\text{F}\{^1\text{H}\}$, CDCl_3 , 376 MHz







anti-26


$^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz






anti-26
2D ^1H - ^1H COSY, CDCl_3








anti-26

2D ^1H - ^{13}C HSQC, CDCl_3









syn-S22


^1H , CDCl_3 , 400 MHz







syn-S22


$^{19}\text{F}\{^1\text{H}\}$, CDCl_3 , 376 MHz







syn-S22
 $^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz









syn-S22
2D ^1H - ^1H COSY, CDCl_3












anti-27


$^{19}\text{F}\{^1\text{H}\}$, CDCl_3 , 376 MHz







anti-27
 $^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz







anti-27
2D ^1H - ^{13}C HSQC, CDCl_3






anti-27
2D ^1H - ^{13}C HMBC, CDCl_3






syn-**S23**

^1H , CDCl_3 , 400 MHz







syn-S23

$^{19}\text{F}\{^1\text{H}\}$, CDCl_3 , 376 MHz


-137.910
-137.933
-137.964
-152.466
-152.489
-152.520
-152.544







syn-S23


$^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz







syn-**S23**
2D ^1H - ^{13}C HSQC, CDCl_3






syn-S23
2D ^1H - ^{13}C HMBC, CDCl_3









anti-**28**


$^{19}\text{F}\{^1\text{H}\}$, CDCl_3 , 470 MHz







anti-**28**


$^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz







anti-28
2D ^1H - ^1H COSY, CDCl_3






anti-28
2D ^1H - ^{13}C HSQC, CDCl_3









anti-29


$^{19}\text{F}\{^1\text{H}\}$, CDCl_3 , 376 MHz







anti-**29**


$^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz







anti-29
2D ^1H - ^1H COSY, CDCl_3






anti-**29**
2D ^1H - ^{13}C HSQC, CDCl_3







anti-**29**
2D ^1H - ^{13}C HMBC, CDCl_3




syn-**S24**
 ^1H , CDCl_3 , 400 MHz







syn-S24


$^{19}\text{F}\{^1\text{H}\}$, CDCl_3 , 376 MHz









syn-S24
2D ^1H - ^1H COSY, CDCl_3







syn-S24


2D ^1H - ^{13}C HSQC, CDCl_3






syn-S24
2D ^1H - ^{13}C HMBC, CDCl_3






anti-**30**


^1H , CDCl_3 , 400 MHz






***anti*-30**


$^{19}\text{F}\{^1\text{H}\}$, CDCl_3 , 376 MHz







anti-30


$^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz







anti-30
2D ^1H - ^1H COSY, CDCl₃






anti-30
2D ^1H - ^{13}C HSQC, CDCl_3







2D ^1H - ^{13}C HMBC, CDCl_3





^1H , CDCl_3 , 500 MHz







syn-S25
 $^{19}\text{F}\{^1\text{H}\}$, CDCl_3 , 376 MHz







syn-S25
 $^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz







syn-S25
2D ^1H - ^1H COSY, CDCl_3






syn-S25
2D ^1H - ^{13}C HSQC, CDCl_3







syn-S25

2D ^1H - ^{13}C HMBC, CDCl_3






anti-**31**





syn-**S26**

^1H , CDCl_3 , 500 MHz


-138.259
-138.280
-138.305
-138.324
-138.330
-138.653
-138.674
-138.699
-138.720
-152.264
-152.271
-152.290
-152.316
-152.335
-152.341
-153.087
-153.108
-153.134
-153.154








anti-31




syn-S26

$^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz




anti-31




syn-S26


2D ^1H - ^1H COSY, CDCl_3



S212





anti-31




syn-S26



2D ^1H - ^{13}C HSQC, CDCl_3










¹H, CDCl₃, 400 MHz




¹⁹F{¹H}, CDCl₃, 470 MHz









$^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz







anti-32




syn-S27

2D ^1H - ^{13}C HSQC, CDCl_3











37

$^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz









37



2D ^1H - ^{13}C HSQC, CDCl_3





37

2D ^1H - ^{13}C HMBC, CDCl_3




38

^1H , CDCl_3 , 500 MHz


ppm


220 225



38


$^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz







38


2D ^1H - ^{13}C HSQC, CDCl_3










(2R,3S,4R)-**39**




(2R,3S,4S)-**S28**



^1H , CDCl_3 , 400 MHz








$^{13}\text{C}\{^1\text{H}\}$, CDCl_3 , 126 MHz







2D ^1H - ^1H COSY, CDCl_3






2D ^1H - ^{13}C HSQC, CDCl_3





(2*R*,3*S*,4*R*)-39




(2*R*,3*S*,4*S*)-S28


2D ^1H - ^{13}C HMBC, CDCl_3

Appendix II: HPLC traces of novel compounds


HPLC data for *anti*-**14**: Chiralcel OD-H (99:1 *n*-hexane : IPA, flow rate 1.5 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*S*,3*R*) 24.4 min, *t*_R (2*R*,3*S*) 29.4 min, >99:1 er.




PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	23.999	50.221
2	33.034	49.779
Total		100.000




PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	24.371	0.330
2	29.361	99.670
Total		100.000




HPLC data for *anti*-**20**: Chiralcel OD-H (90:10 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*S*,3*R*) 19.3 min, *t*_R (2*R*,3*S*) 22.7 min, 99:1 er.




PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	19.133	50.248
2	22.995	49.752
Total		100.000




PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	19.319	0.767
2	22.714	99.233
Total		100.000




HPLC data for *syn-S17*: Chiralcel OD-H (90:10 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t_R* (2*S*,3*S*) 11.7 min, *t_R* (2*R*,3*R*) 16.1 min, 96:4 er.




PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	11.566	49.852
2	16.213	50.148
Total		100.000




PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	11.673	3.847
2	16.092	96.153
Total		100.000




HPLC data for *anti*-**21**: Chiralcel AD-H (90:10 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*R*,3*S*) 11.3 min, *t*_R (2*S*,3*R*) 14.7 min, 99:1 er.




PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	11.092	49.724
2	14.715	50.276
Total		100.000




PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	11.260	99.284
2	14.710	0.716
Total		100.000




HPLC data for *anti*-**22**: Chiralpak IA (97:3 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*R*,3*S*) 10.1 min, *t*_R (2*S*,3*R*) 14.6 min, 99:1 er.




PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	10.124	50.049
2	14.733	49.951
Total		100.000




PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	10.124	99.401
2	14.613	0.599
Total		100.000




HPLC data for *syn*-**S18**: Chiralpak AD-H (97:3 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*R*,3*R*) 10.8 min, *t*_R (2*S*,3*S*) 15.8 min, 91:9 er.




PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	10.729	49.730
2	15.694	50.270
Total		100.000




PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	10.791	90.714
2	15.808	9.286
Total		100.000




HPLC data for *anti*-**23**: Chiralcel OD-H (99.5:0.5 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*S*,3*R*) 40.6 min, *t*_R (2*R*,3*S*) 47.8 min, 91:9 er.




PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	40.364	49.702
2	49.144	50.298
Total		100.000




PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	40.557	9.201
2	47.579	90.799
Total		100.000




HPLC data for *syn*-**S19**: Chiralcel OD-H (93:7 *n*-hexane : IPA, flow rate 1.5 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*S*,3*S*) 7.3 min, *t*_R (2*R*,3*R*) 11.4 min, 83:17 er.




PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	7.267	49.797
2	11.453	50.203
Total		100.000




HPLC data for *anti*-**24**: Chiralcel OD-H (97:3 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*R*,3*S*) 27.6 min, *t*_R (2*S*,3*R*) 31.2 min, 97:3 er.




PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	28.309	49.908
2	31.401	50.092
Total		100.000




PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	27.557	97.161
2	31.243	2.839
Total		100.000




HPLC data for *syn-S20*: Chiralpak IB (98:2 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*S*,3*S*) 22.6 min, *t*_R (2*R*,3*R*) 29.1 min, 87:13 er.



PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	22.483	49.935
2	28.828	50.065
Total		100.000




HPLC data for *anti*-**25**: Chiralcel OD-H (95:5 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*S*,3*S*) 12.3 min, *t*_R (2*R*,3*R*) 19.9 min, 99:1 er.




PDA Ch1 211nm

Peak#	Ret. Time	Area%
1	12.074	49.991
2	19.178	50.009
Total		100.000




PDA Ch1 211nm


Peak#	Ret. Time	Area%
1	12.300	98.807
2	19.853	1.193
Total		100.000




HPLC data for *syn*-**S21**: Chiralcel OD-H (99:1 *n*-hexane : IPA, flow rate 1.5 mLmin⁻¹, 211 nm, 40 °C) *t*_R (2*R*,3*S*) 16.4 min, *t*_R (2*S*,3*R*) 23.3 min, 97:3 er.




PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	16.517	50.262
2	23.940	49.738
Total		100.000



PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	16.359	3.170
2	23.281	96.830
Total		100.000




HPLC data for *anti*-**26**: Chiralcel OD-H (93:7 *n*-hexane : IPA, flow rate 2.0 mLmin⁻¹, 211 nm, 30 °C) *t_R* (2*S*,3*R*) 7.0 min, *t_R* (2*R*,3*S*) 12.6 min, 98:2 er.




PDA Ch1 211nm

Peak#	Ret. Time	Area%
1	6.907	50.194
2	12.564	49.806
Total		100.000




PDA Ch1 211nm


Peak#	Ret. Time	Area%
1	6.990	2.312
2	12.621	97.688
Total		100.000




HPLC data for *syn*-**S22**: Chiralcel OD-H (95:5 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*S*,3*S*) 10.7 min, *t*_R (2*R*,3*R*) 24.6 min, 87:13 er.




PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	10.514	49.885
2	23.920	50.115
Total		100.000




PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	10.690	13.038
2	24.567	86.962
Total		100.000




HPLC data for *anti*-**27**: Chiralcel OD-H (93:7 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 40 °C) *t*_R (2*S*,3*R*) 25.3 min, *t*_R (2*R*,3*S*) 46.2 min, 99:1 er.




PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	25.230	50.037
2	46.448	49.963
Total		100.000



PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	25.347	0.781
2	46.167	99.219
Total		100.000




HPLC data for *syn*-**S23**: Chiralcel OD-H (93:7 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 40 °C) *t*_R (2*S*,3*S*) 16.9 min, *t*_R (2*R*,3*R*) 34.7 min, 99:1 er.




PDA Ch1 211nm

Peak#	Ret. Time	Area%
1	16.844	50.233
2	36.873	49.767
Total		100.000




PDA Ch1 211nm


Peak#	Ret. Time	Area%
1	16.944	1.183
2	34.659	98.817
Total		100.000




HPLC data for *anti*-**28**: Chiralcel OD-H (95:5 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*S*,3*R*) 16.4 min, *t*_R (2*R*,3*S*) 23.4 min, 99:1 er.




PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	16.020	49.928
2	22.924	50.072
Total		100.000




PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	16.428	1.419
2	23.384	98.581
Total		100.000




HPLC data for *anti*-**29**: Chiralcel OD-H (95:5 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*S*,3*R*) 16.8 min, *t*_R (2*R*,3*S*) 27.9 min, 99:1 er.




PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	16.876	49.951
2	28.173	50.049
Total		100.000



PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	16.768	1.437
2	27.894	98.563
Total		100.000




HPLC data for *syn*-**S24**: Chiralcel OD-H (93:7 *n*-hexane : IPA, flow rate 1.5 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*S*,3*S*) 6.5 min, *t*_R (2*R*,3*R*) 11.6 min, 96:4 er.




PDA Ch1 211nm

Peak#	Ret. Time	Area%
1	6.571	49.530
2	12.039	50.470
Total		100.000




PDA Ch1 211nm


Peak#	Ret. Time	Area%
1	6.516	4.194
2	11.615	95.806
Total		100.000




HPLC data for *anti*-**30**: Chiralcel OD-H (97:3 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*S*,3*R*) 25.8 min, *t*_R (2*R*,3*S*) 31.2 min, 97:3 er.




PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	24.838	50.416
2	32.031	49.584
Total		100.000



PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	25.816	2.727
2	31.215	97.273
Total		100.000





HPLC data for *syn*-**S25**: Chiralcel OD-H (97:3 *n*-hexane : IPA, flow rate 1.5 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*S*,3*S*) 12.3 min, *t*_R (2*R*,3*R*) 21.0 min, 89:11 er.




syn-**S25**

PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	12.405	49.726
2	22.268	50.274
Total		100.000




HPLC data for *anti*-**31**: Chiralpak AD-H (99:1 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*S*,3*R*) 16.2 min, *t*_R (2*R*,3*S*) 18.3 min, 99:1 er.


HPLC data for *syn*-**S26**: enantiomeric ratio could not be determined.



PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	16.268	38.009
2	18.497	37.202
3	28.319	24.789
Total		100.000




PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	16.184	0.399
2	18.327	52.834
3	27.891	46.766
Total		100.000



HPLC data for *anti*-**32**: Chiralcel OD-H (98:2 *n*-hexane : IPA, flow rate 1.5 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*S*,3*R*) 15.6 min, *t*_R (2*R*,3*S*) 19.0 min, 99:1 er.


HPLC data for *syn*-**S27**: Chiralcel OD-H (98:2 *n*-hexane : IPA, flow rate 1.5 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*S*,3*S*) 12.2 min, *t*_R (2*R*,3*R*) 25.4 min, 96:4 er.



PDA Ch1 211nm

Peak#	Ret. Time	Area%
1	12.261	12.118
2	15.605	38.038
3	19.963	37.688
4	26.156	12.156
Total		100.000


mAU




PDA Ch1 211nm

Peak#	Ret. Time	Area%
1	12.157	0.709
2	15.568	0.852
3	18.971	82.166
4	25.430	16.272
Total		100.000


mAU




HPLC data for **37**: Chiralpak IB (90:10 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*S*,3*R*) 8.8 min, *t*_R (2*R*,3*S*) 14.0 min, >99:1 er.




PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	8.750	50.069
2	14.086	49.931
Total		100.000



PDA Ch1 211nm		
Peak#	Ret. Time	Area%
1	14.027	100.000
Total		100.000




HPLC data for **38**: Chiralcel OD-H (99:1 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 30 °C) *t*_R (2*R*,3*S*) 19.4 min, *t*_R (2*S*,3*R*) 23.7 min, >99:1 er.




38

Detector A Channel 1 211nm		
Peak#	Ret. Time	Area%
1	19.025	50.477
2	23.724	49.523
Total		100.000




Detector A Channel 1 211nm		
Peak#	Ret. Time	Area%
1	19.423	100.000
Total		100.000




HPLC data for (2*R*,3*S*,4*R*)-**39**: Chiralpak ID (93:7 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 40 °C) *t_R* (2*R*,3*S*,4*R*) 23.1 min, *t_R* (2*S*,3*R*,4*S*) 24.3 min, >99:1 er.

HPLC data for (2*R*,3*S*,4*S*)-**S28**: Chiralpak ID (93:7 *n*-hexane : IPA, flow rate 1.0 mLmin⁻¹, 211 nm, 40 °C) *t_R* (2*S*,3*R*,4*R*) 21.6 min, *t_R* (2*R*,3*S*,4*S*) 33.7 min, >99:1 er.



Detector A Channel 1 211nm		
Peak#	Ret. Time	Area%
1	21.586	5.269
2	23.092	42.848
3	24.315	47.554
4	33.998	4.329
Total		100.000



Detector A Channel 1 211nm		
Peak#	Ret. Time	Area%
1	23.116	90.582
2	33.703	9.418
Total		100.000

